Compositions and methods of hematopoietic stem cell transplants

ABSTRACT

The present disclosure provides distinct therapeutic populations of cells that form a pharmaceutical composition useful in hematopoietic stem/progenitor cell transplant. For example, the present disclosure provides a therapeutic population of cells, comprising an enriched population of hematopoietic stem/progenitor cells, memory T cells, regulatory T cells, and wherein the population of cells is depleted of naïve conventional αβ-T cells. The present disclosure further provides methods of treatment using the therapeutic population of cells. In other embodiments, the present disclosure provides methods of producing a therapeutic population of cells.

CROSS REFERENCE TO RELATED APPLICATION

This application claims the benefit under 35 U.S.C. § 119(e) to U.S.Provisional Application No. 62/471,769, filed Mar. 15, 2017, whichapplication is hereby incorporated by reference in its entirety.

BACKGROUND

Allogeneic hematopoietic stem cell transplantation (HSCT) generallyinvolves transferring the hematopoietic cells from an immunologicallycompatible healthy person (the donor) to a patient after a conditioningregimen. Healthy hematopoietic stem cells (HSC) can replace the damagedhematopoietic tissue of a patient, and specific donor derived immunecells can have a therapeutic effect on cancer, infections, andimmunological diseases. However, the current methods of allogeneic HSCTinclude either a heterogeneous mixture of cells that includecontaminating, non-therapeutic cells or a purified, but limited mixtureof cells that lacks the potential therapeutic benefit of a completegraft. In the former scenario, while many of the non-therapeutic cellscontaminating the therapeutically relevant cells are harmless, even asmall population of a specific errant cell type can cause severelyadverse consequences in the recipient. For example, residual tumorcells, or teratoma initiating cells, that contaminate a population oftransplanted cells can seed a tumor in a patient. In another example,subsets of circulating T cells can initiate graft-versus-host-disease(GVHD) a serious and often fatal complication of allogeneic HSCT. Inthese instances, the pathology arising from the contaminating cellssupersedes the therapeutic benefits of other T cells introduced duringtransplantation. In many cases allogeneic HSCT is a curative therapy forthe underlying disorder, however when contaminating cells of the graftreact against to their new host environment, it is indeed the medicaltreatment that does harm to the patient. Therefore, there is a high,unmet need for HSC transplant compositions with a reduced number ofdeleterious cells and an optimal mixture of therapeutic cells.

SUMMARY

In some embodiments disclosed herein is a pharmaceutical composition,comprising one or more unit doses of a cellular graft, wherein each unitdose of the cellular graft comprises populations of therapeutic cellsfor each kilogram (kg) of body weight of a subject receiving thecellular graft. In some embodiments, the populations of therapeuticcells of each unit dose comprise more than 3×10⁵ hematopoieticstem/progenitor cells (HSPC), more than 3×10⁵ memory T cells (Tmem),more than 5×10⁵ regulatory T cells (Treg), and less than 3×10⁵ naïveconventional αβ-T cells. In some embodiments, the unit dose furthercomprises 0.5×10³ to 2000×10³ invariant natural killer T (iNKT) cells.In some embodiments, the HSPC are CD34⁺, the Tmem areCD3⁺CD45RA⁻CD45RO⁺, the Treg are CD4⁺CD25⁺CD127^(−/lo), CD45RA⁺, or acombination thereof, and the naïve conventional αβ-T cells areCD3⁺CD45RA⁺CD25⁻Va24Ja18⁻. In some embodiments, the iNKT areCD3⁺Vα24Jα18⁺.

In some embodiments, the pharmaceutical composition disclosed hereincomprises a population of therapeutic cells that is enriched for HSPC),memory T cells (Tmem), and Treg, and wherein the population of cells isdepleted of naïve conventional αβ-T cells, wherein the population oftherapeutic cells comprises a ratio of naïve conventional αβ-T cells toTreg less than 1:5. In some embodiments, the pharmaceutical compositionfurther comprises invariant iNKT and the population of therapeutic cellscomprises a ratio of naïve conventional αβ-T cells to iNKT less than100:1. In some embodiments, the population of therapeutic cellscomprises, a ratio of naïve conventional αβ-T cells to HSPC that is lessthan 1:400; and a ratio of naïve conventional αβ-T cells to Tmem lessthan 1:800. In some embodiments, the population of therapeutic cellscomprises iNKT and population of therapeutic cells comprises a ratio ofnaïve conventional αβ-T cells to HSPC less than 1:400; a ratio of naïveconventional αβ-T cells to Tmem less than 1:800; and a ratio of naïveconventional αβ-T cells to iNKT is less than 100:1. In some embodiments,the population of therapeutic cells comprises a ratio of naïveconventional αβ-T cells to HSPC less than 1:400. In some embodiments,the population of therapeutic cells comprises a ratio of naïveconventional αβ-T cells to Tmem less than 1:3.

In some embodiments disclosed herein is a method of treating a diseaseor disorder, comprising administering a therapeutic population of cellsto a subject in need thereof, wherein the therapeutic population ofcells comprises HSPC at a concentration of 1.0×10⁶ to 50×10⁶ cells/kg ofsubject weight, Tmem at a concentration of 0.1×10⁶ to 1000×10⁶ cells/kgof subject weight, Treg at a concentration of 0.1×10⁶ to 1000×10⁶cells/kg of subject weight, and naïve conventional αβ-T at aconcentration of less than 3×10⁵ cells/kg of subject weight. In someembodiments, the therapeutic population of cells further comprises iNKTcells at a concentration of 0.5×10³ to 2000×10³ cells/kg of subjectweight.

In some embodiments, disclosed herein is a method of producing apharmaceutical composition comprising, processing at a least one sampleto provide a population of therapeutic cells by:

A. contacting the sample with a binding molecule that specifically bindsCD34 under conditions to provide a population enriched for CD34⁺ cellsand a population of CD34-depeleted cells, recovering the populationenriched for CD34⁺ cells, and recovering the population of CD34-depletedcells; and

B. contacting the population of CD34-depleted cells with a bindingmolecule that specifically binds CD25 under conditions to provide apopulation enriched for CD25⁺ cells and a population of CD25-depletedcells, recovering the population enriched for CD25⁺ cells, andrecovering the population of CD25-depleted cells; and

C. contacting the population of CD25-depleted cells with a bindingmolecule that specifically binds CD45RA under conditions to provide apopulation enriched for CD45RA⁺ cells and a population ofCD45RA-depleted cells, and recovering a population of CD45RA-depletedcells; and

D. formulating the population enriched for CD34+ cells, the populationenriched for CD25⁺ cells and the population of CD45-depleted cells as apharmaceutical composition suitable for administration to a subject.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A-B: FIG. 1A shows a schematic representation of a process forproducing a sculpted graft cellular composition. FIG. 1B shows aschematic representation of a process for producing a sculpted graftcellular composition.

FIG. 2A-B: FIG. 2A shows a schematic representation of a process forproducing a sculpted graft cellular composition. FIG. 2B shows aschematic representation of a process for producing a sculpted graftcellular composition.

FIG. 3 shows a schematic representation of a process for producing asculpted graft cellular composition.

FIG. 4 shows a schematic representation of a process for producing asculpted graft cellular composition.

FIG. 5 shows a schematic representation of a process for producing asculpted graft cellular composition.

FIG. 6 shows a schematic representation of a process for producing asculpted graft cellular composition.

FIG. 7 shows a schematic representation of a process for producing asculpted graft cellular composition.

FIG. 8 shows a schematic representation of a process for producing asculpted graft cellular composition.

FIG. 9 shows a schematic representation of a process for producing asculpted graft cellular composition.

FIG. 10 shows a schematic representation of a process for producing asculpted graft cellular composition.

FIG. 11 shows a schematic representation of a process for producing asculpted graft cellular composition.

FIG. 12 shows a schematic representation of a process for producing asculpted graft cellular composition.

FIG. 13 shows a schematic representation of a process for producing asculpted graft cellular composition.

FIG. 14 shows a schematic representation of a process for producing asculpted graft cellular composition.

FIG. 15 shows a schematic representation of a process for producing asculpted graft cellular composition.

FIG. 16 depicts an experimental design to assess the performance of asculpted cellular graft compared to bone marrow transplant (BMT) andhematopoietic stem cell transplant (HSCT) compositions.

FIG. 17A-D shows the performance of a sculpted cellular graft comparedto bone marrow transplant (BMT) and hematopoietic stem cell transplant(HSCT) compositions. FIG. 17A. Kaplan-Meier curves of percent survivalover time. FIG. 17B. Final outcomes assessed as overall survival,relapse, engraftment failure, and GVHD. FIG. 17C. Exemplary micrographof J774 GPF-Luc tumors in the spleen dissected from a HSCT mouse. FIG.17D. Representative bioluminiescent image comparing presence of GFP+cells generated using a Xenogen IVIS100 on day +10.

FIG. 18 depicts Kaplan-Meier curves of percent survival of mice treatedwith a sculpted cellular graft produced with magnetic sorting (MACS) andfluorescence activated sorting (FACS) in comparison to a sculptedcellular graft produced with MACS-only.

FIG. 19 depicts Kaplan-Meier curves showing survival of mice that wereadministered a sculpted cellular graft versus mice administered CD34⁺cellular compositions that include T cells added back after isolation.

FIG. 20 depicts Kaplan-Meier curves showing survival mice in a xenograftmodel of adoptive transfer wherein the cohorts of mice were administereither a human PBMCs or a sculpted cellular graft composition derivedfrom human tissue.

FIG. 21A-B depicts enrichment of regulatory T cells and iNKT cells fromperipheral blood monocytes (PBMCs) using MACS. FIG. 21A shows flowcytometry data showing the % purity and % yield of Tregs in pre-sortPBMCs and enriched populations. FIG. 21B shows flow cytometry datashowing the % purity and % yield of iNKT cells in the pre-sort PBMCs andenriched populations.

FIG. 22A-B depicts enrichment of memory T cells from PBMCs usingmagnetic sorting. FIG. 22A shows % yield of CD3⁺CD45RO⁺ cells and ratioof naïve T:memory T cells produced using magnetic sorting of PBMCs. FIG.22B shows flow cytometry data showing CD45RO and CD45RA cells in pooledPBMCs and CD45RA depleted samples.

FIG. 23A-B depicts magnetic separation of CD25⁺ cells. FIG. 23A showsflow cytometry analysis of magnetically separated CD25+ cellsdemonstrating efficient separation of CD25+CD127+ Treg andcharacterizing the subpopulations of memory Treg and naïve Treg cells.FIG. 23B shows exemplary performance of the magnetic separation strategyfor Treg and naïve Treg from two donors.

FIG. 24A-B depicts biotinylation titration of 6B11 antibodies. FIG. 24Ashows binding of the 6B11.1, 6B11.2, and 6B11.3 biotinylated antibodiesto samples for three separate donors at increasing concentrations of6B11 antibody from zero to 1 μg/μL. FIG. 24B shows flow cytometryanalysis of 6B11 biotin/streptavidin PE-Cy7 staining and CD127 APCstaining to a sample using a no-6B11 control or 6B11 antibody that wasbiotinylated with biotin at 100 μM (condition 1), 250 μM (condition 2),or 1 mM (condition 3).

DETAILED DESCRIPTION

In certain embodiments, the present disclosure provides distincttherapeutic populations of cells that form a pharmaceutical compositionuseful in hematopoietic stem/progenitor cell transplant. For example,some embodiments of the present disclosure provides a therapeuticpopulation of cells, comprising an enriched population of hematopoieticstem/progenitor cells (HSPC), memory T cells (Tmem), regulatory T cells(Treg), and wherein the population of cells is depleted of naïveconventional αβ-T cells. In some embodiments, the therapeutic populationof cells further comprises invariant Natural Killer T (iNKT) cells. Thepresent disclosure further provides methods of treatment using thetherapeutic population of cells. In other embodiments, the presentdisclosure provides methods of producing a therapeutic population ofcells.

The therapeutic cell populations have been sculpted to enrich the numberof cells with therapeutic benefit and deplete the cell populations thatare detrimental to a graft recipient (e.g., induce secondary disease).HSPC provide for short term benefits of reconstitution of blood andimmune system functions such as restoring red blood cell, platelet, andneutrophil counts. Durable engraftment of HSPC provides forreconstitution of adaptive immune functions by producing T cell and Bcell populations. Donor T cells as a general population are bothbeneficial and detrimental to engraftment. Tmem cells provide a benefitbecause Tmem mediate both Graft vs. Infection effects and Graft vs.Leukemia effects with a reduced risk of Graft versus Host Disease(GVHD). Naïve and memory Treg cells provide a benefit because Tregs helpprevent graft rejection and prevent GVHD. In contrast, naïveconventional T cells are a cause of GVHD and improper immunereconstitution. Therefore, reducing or eliminating naïve conventional Tcells in the sculpted graft disclosed herein enhances the therapeuticbenefit by reducing the incidence of GVHD in the graft recipient.

Definitions

In the present description, any concentration range, percentage range,ratio range, or integer range is to be understood to include the valueof any integer within the recited range and, when appropriate, fractionsthereof (such as one tenth and one hundredth of an integer), unlessotherwise indicated. Also, any number range recited herein relating toany physical feature, such as polymer subunits, size or thickness, areto be understood to include any integer within the recited range, unlessotherwise indicated. As used herein, the term “about” means±20% of theindicated range, value, or structure, unless otherwise indicated. Theterm “consisting essentially of” limits the scope of a claim to thespecified materials or steps, or to those that do not materially affectthe basic and novel characteristics of the claimed invention. It shouldbe understood that the terms “a” and “an” as used herein refer to “oneor more” of the enumerated components. The use of the alternative (e.g.,“or”) should be understood to mean either one, both, or any combinationthereof of the alternatives. As used herein, the terms “include,” “have”and “comprise” are used synonymously, which terms and variants thereofare intended to be construed as non-limiting.

As used herein, the term “therapeutic cell” refers to a cell that isselected or administered to a subject based on the ability of the cellto offer a therapeutic benefit to a subject. Exemplary therapeutic cellsinclude hematopoietic stem/progenitor cells, memory T cells, regulatoryT cells, and invariant natural killer T cells. A population oftherapeutic cells can include more than one type of therapeutic cell,e.g., HSPC, Tmem, Treg, iNKT or any combination thereof. A population oftherapeutic cells can comprise essentially a single therapeutic celltype. In the context of a population of therapeutic cells, a percentage(%) of therapeutic cells refers to the percent of a cell-type that isincluded in a combination or composition of therapeutic cells in whichthe total number of therapeutic cells adds up to 100% and the specifictherapeutic cell type represents a portion of the total number oftherapeutic cells. For example, a population therapeutic cellscomprising 30% HSPC indicates that approximately 30% of the totalpopulation of therapeutic cells is HSPC. A population of therapeuticcells can exist within a larger population of cells that have a neutraleffect on the subject and the neutral cells are not included in thecalculation of total therapeutic cells.

As used herein, the term “hematopoietic stem/progenitor cells” or “HSPC”refer to hematopoietic stem cells and/or hematopoietic progenitor cellsthat express increased levels of phenotypic markers CD34, CD133, CD90,or any combination thereof, relative to other types of hematopoieticcells (e.g., the cells are positive for expression of the phenotypicmarker as determined by flow cytometry, western blot, or other methodsknown in the art). Also, the HSPC can be negative for an expressedmarker relative to other types of hematopoietic cells. For example, suchmarkers include CD19, TCRα, TCRβ, CD45RA, Lin, CD38, or any combinationthereof. Preferably, the HSPC are CD34⁺ cells and/or CD19⁻ TCRα⁻. HSPCcan self-renew or can differentiate into (i) myeloid progenitor cells,which ultimately give rise to monocytes and macrophages, neutrophils,basophils, eosinophils, erythrocytes, megakaryocytes/platelets, ordendritic cells; or (ii) lymphoid progenitor cells which ultimately giverise to T-cells, B-cells, and lymphocyte-like cells called naturalkiller cells (NK-cells). For a general discussion of hematopoiesis andHSPC differentiation, see Rowe et al. Cell Stem Cell. 2016. 18:707-720.

As used herein, the term “naïve conventional αβ-T cells” or “naïve Tcon”refers to a non-antigen experienced T cell that expresses the phenotypicmarkers TCRα/β, CD45RA, and expresses medium to high levels of CD127(CD127⁺), and does not express or has low expression of CD45RO and CD25.In some embodiments, naïve Tcon are characterized by the expression ofphenotypic markers of naïve Tcon including TCRα, TCRβ, CD3, CD4 or CD8,CD62L, CCR7, CD28, CD127, and CD45RA. In some embodiments a naïve Tconis CD3⁺ CD25⁻ CD45RA⁺ and comprises a polymorphic TCRα, and apolymorphic TCRβ. In some embodiments, naïve Tcon are not naïve Tregulatory cells, as defined herein. Naïve Tcon cells do not express theVα24Jα18 TCR found on iNKT cells.

As used herein, the term “regulatory T cell” or “Treg” refers to asubclass of T cell that is capable of suppressing autoimmune reactionsand expresses the phenotypic markers CD4, CD25, and has no or lowexpression of CD127. Treg also express FOXP3, however, CD127 expressionhas been demonstrated to correlate inversely with FOXP3 expression onCD4⁺CD25⁺ cells, and the CD4⁺CD25⁺CD127^(−/low) phenotype is consideredto be an acceptable surrogate marker for Tregs and a practicalalternative to intracellular staining for FOXP3 (Cozzo C, et al. JImmunol. 2003 Dec. 1; 171:5678-82; Liu W, et al. J Exp. Med. 2006.203(7):1701-1711; Seddiki N, et al. J Exp. Med. 2006; 203(7):1693-1700).Tregs can include at least two subclasses referred to herein as naïveTregs and memory Tregs.

As used herein, the term “naïve Treg” is a non-antigen experiencedregulatory T cell that expresses the phenotypic markers CD4, CD25, andCD45RA as a primary cell, and does not express or has low expression ofCD45RO and CD127. Naïve Tregs are advantageous because the cells havehigher plasticity for responding to antigens than antigen experiencedTregs. In addition, naïve Tregs have increased longevity compared toantigen experienced Tregs.

As used herein, the term “memory Treg” is an antigen experiencedregulatory T cell that is capable of providing suppressive effects onautoimmunity and expresses the phenotypic markers CD4, CD25, and CD45ROand does not express or has low expression of CD127 and CD45RA.

As used herein, the term “memory T cell” or “Tmem” refers to antigenexperienced T cells that express the phenotypic markers TCRα, TCRβ, CD3,CD4 or CD8, CD95, and IL-2Rβ. Memory T cells provide immunity and arecapable of persisting for a long period of time in an inactive state.Memory T cells are able to rapidly acquire effector functions uponre-challenge with antigen. A population of memory T cells can includethe any combination of the subclasses T central memory cells (T_(CM))and T effector memory cells (T_(EM)).

As used herein, “T central memory cell” or “T_(CM)” refers to an antigenexperienced T cell that expresses the phenotypic markers CD4 or CD8,CD62L, CD45RO, CCR7, CD28, CD127, and CD95 and does not express or haslow expression of CD45RA as compared to naïve Tcon cells. Central memoryT cells can differentiate into T_(EM) cells following antigenre-challenge.

As used herein, “T effector memory cell” or “T_(EM)” refers to anantigen experienced T cell that expresses the phenotypic markers CD4 orCD8, CD45RO, CD127, IL-2Rβ, and CD95, and does not express or has lowexpression of CD45RA, CD62L, CCR7, and CD28. T effector memory cell areterminally differentiated and acquire effector function afterre-stimulation by antigen.

As used herein, “T stem central memory cell” or “T_(SCM)” refers to anantigen experienced T cell that expresses the phenotypic markers CD4 orCD8, CD45RA, CD62L, CD95, CCR7, CXCR3, CD122, and LFA-1. T_(SCM) cellspossess memory T cell capability of rapid acquisition of effectorfunction following antigen re-challenge, but have enhanced stemcell-like qualities such as long-term persistence compared to T_(CM)cells. T_(SCM) cells can generate central memory, effector memory, andeffector T cell subsets.

As used herein, “invariant Natural Killer T cells” or “iNKT” is asubclass of CD1d-restricted Natural Killer T (NKT) cells that express ahighly conserved αβ-T cell receptor that comprises of Vα24Jα18 TCRαchain in humans (referred to herein as “Vα24Jα18⁺”). iNKT cells can beidentified by binding with CD1d-multimers like that are loaded withα-galactosylceramide (GalCer), PBS-57, PBS-44 or other natural orsynthetic glycolipids, and can be found as tetramers, dendrimers, andother structures, Fc fusions, or any combination thereof. Another methodof identification is an antibody or combination of antibodies thatspecifically recognize the Vα24Jα18 region. Examples include a Va24antibody, a Jα18 antibody, or the monoclonal antibody clone 6B11 whichbinds specifically to a unique region of the Vα24Jα18 TCR and can beused to identify iNKT cells (Montoya et al. Immunology. 2007.122(1):1-14). In some embodiments, iNKT cells are CD1d-tetrimerglycolipid loaded⁺ (CD1d-tet⁺), 6B11⁺, or both. iNKT cells may beinterchangeably referred to herein as CD1d-tet⁺, 6B11⁺, or Vα24Jα18⁺cells. Without wishing to be limited to a particular mechanism, it isthought that iNKT cells promote/accelerate the activity of Treg andHSPC.

As referred to herein, “lineage positive” or “Lin⁺” cells express thephenotypic markers such as CD19, CD11c, CD66B, CD14, CD20, or anycombination thereof. As referred to herein, “lineage negative” or “Lin”cells do not express or have low expression of the phenotypic markersCD19, CD11c, CD66B, CD14, CD20, or any combination thereof compared toHSPC, Treg, Tmem, or iNKT cells. Lin⁺ cells express phenotypic markersthat are present on mature erythroid cells, granulocytes, macrophages,NK cells, and B and T lymphocytes.

As used herein, “sample” refers to a cell source (e.g. biologicaltissue) from which a population of cells may be isolated, enriched, ordepleted. In some embodiments, a sample has generally not beenpreviously processed or has been minimally processed. For example, thesample may be mobilized peripheral blood, mobilized apheresis product,bone marrow, umbilical cord blood, non-mobilized blood, non-mobilizedapheresis product, or any combination thereof. In some embodiments, thesample is prepared or minimally processed by processing with a densitygradient, Ficoll, Percoll, red blood cell hypotonic lysis,Ammonium-Chloride-Potassium (ACK) buffer, washed into a pH balancedisotonic buffer, or any combination thereof. In some embodiments, thesample is provided by a single tissue harvest. In some embodiments, thesample is provided by one or more tissue harvests.

As used herein, “donor” refers to one or more individuals from which asample is obtained. For example, a donor may refer to an human leukocyteantigen (HLA) matched sibling, an HLA matched unrelated donor, apartially matched unrelated donor, a haploidentical related donor,autologous donor, an HLA unmatched allogenic donor, a pool of donors, orany combination thereof. In some embodiments a donor may be a subject.“Donor tissue” refers to tissue harvested from a donor. Donor tissue canbe a sample. The donor tissue is generally the same species as thesubject.

As used herein, “subject” or “recipient” refers to one or moreindividuals that are in need of receiving treatment, therapy, orcellular graft disclosed herein. Subjects that can be treated by thepresent invention are, in general, human. However, additional subjectsinclude a non-human primate, cow, horse, sheep, goat, pig, dog, cat,mouse, rabbit, rat, or Guinea pig. The subjects can be male or femaleand can be any suitable age, including infant, juvenile, adolescent,adult, and geriatric subjects. During and following the treatment, asubject becomes a recipient or graft recipient.

As used herein, “tissue harvest” refers a process of collecting a donortissue or a sample from a donor. Non-limiting examples of a tissueharvest include collecting bone marrow, peripheral blood, umbilical cordblood, etc. from a donor. A tissue harvest may be performed by anymethod which known in the art.

As used herein, “enriched” with respect to a population of a cells orcell-types in a mixture refers a population of cells that has beenprocessed to increase the relative amount or ratio of the enrichedcell-type relative to other cells (e.g., accounting cell-types) in themixture. Thus, depending upon the source of the original population ofcells subjected to the enriching process, a mixture or composition cancontain 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%,91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more (in number orcount) of the “enriched” population of cells relative to other cells inthe mixture. In some embodiments, the enrichment process can result in a1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold,9-fold, 10-fold, 15-fold, 20-fold, 25-fold, 30-fold, 35-fold, 40-fold,50-fold, 100-fold, 200-fold, 300-fold, 400-fold, 500-fold, 600-fold,700-fold, 800-fold, 900-fold, 1,000-fold, 5,000-fold, 10,000-fold ormore of the “enriched” population of cells relative to other cells inthe mixture. For example, in some embodiments, a mixture of cells thatis enriched for iNKT cells may comprise about 0.03 to 1% iNKT cells,0.05% to 0.5% iNKT cells, 0.1% to 1% iNKT cells, or any combinationthereof. Exemplary methods of enriching a cell population includemagnetic activated cell sorting (MACS) and fluorescence activated cellsorting (FACS).

As used herein, “depleted” with respect to a population of a cells orcell-types in a mixture refers a population of cells that has beenprocessed to decrease the relative amount or ratio of the depletedcell-type relative to other cells (e.g., accounting cell-types) in themixture. In some embodiments, cells subjected to a depleting process canresult in a mixture or composition containing 50%, 45%, 40%, 35%, 30%,25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or 0.1%, 0.01%,0.001%, 0.0001%, 0.00001%, 0.000001%, 0.0000001%, 0.00000001% or less(in number or count) of the “depleted” population of cells. In someembodiments, cells subjected to a depleting process can results in amixture or composition containing 10-fold, 100-fold, 1,000-fold,10,000-fold, 100,000-fold, 1,000,000-fold, 10,000,000-fold, or less ofthe depleted population relative to the unprocessed sample. In someembodiments, the depleted cell-type is no longer detectable usingconventional methods following the processing step that depletes thecell-type.

In certain embodiments, amounts of a certain cell type in a mixture areenriched and amounts of a different cell type are depleted, such asenriching for CD34⁺ cells while depleting CD34⁻ cells.

A cell population “positive” for a marker refers to uniform staining ofthe cell population above the levels found on an isotype control. Insome embodiments, a decrease in or low expression of one or more markersrefers to a loss of or measure of at least 1 log 10 in the meanfluorescence intensity (MFI) less than a reference control. In someembodiments, an increase in or high expression of one or more markersrefers to an increase or measure of MFI at least 1 log 10 higher than anisotype control or reference control. In some embodiments, an at least2-fold increase in the MFI relative to the reference populationindicates the cells are positive for expression of the marker. Forexample, a cell population that is positive for a marker can demonstratea 2-fold to 4 fold, 4 fold to 10 fold, 10 fold to 100 fold, and 100 foldto 1,000 fold, 1,000 fold to 10,000 fold, 2-fold, 3-fold, 4-fold,5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 15-fold, 20-fold,25-fold, 30-fold, 35-fold, 40-fold, 50-fold, 100-fold, 200-fold,300-fold, 400-fold, 500-fold, 600-fold, 700-fold, 800-fold, 900-fold,1,000-fold, 5,000-fold, 10,000-fold or more higher MFI compared to anisotype control. In some embodiments, a cell population positive for ofone or more markers refers to a percentage of cells that exhibit themarker, which can be at least 50% of the cells, 55% of the cells, 60% ofthe cells, 65% of the cells, 70% of the cells, 75% of the cells, 80% ofthe cells, 85% of the cells, 90% of the cells, 95% of the cells, and100% of the cells and any % between 50% and 100% when compared to areference cell population.

A cell population “negative” for a marker refers to the absence ofsignificant staining of the cell population with the specific antibodyabove an isotype control. In some embodiments, an at least 2-folddecrease in the MFI relative to the reference population indicates thecells are negative for expression of the marker. For example, a cellpopulation that is negative for a marker can demonstrate a 2-fold to 4fold, 4 fold to 10 fold, 10 fold to 100 fold, and 100 fold to 1,000fold, 1,000 fold to 10,000 fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold,7-fold, 8-fold, 9-fold, 10-fold, 15-fold, 20-fold, 25-fold, 30-fold,35-fold, 40-fold, 50-fold, 100-fold, 200-fold, 300-fold, 400-fold,500-fold, 600-fold, 700-fold, 800-fold, 900-fold, 1,000-fold,5,000-fold, 10,000-fold or more lower MFI compared to a positivecontrol. In some embodiments, a decrease in or low expression of one ormore markers refers to a percentage decrease of cells that exhibit themarker in a population of cells of at least 20% of the cells, 25% of thecells, 30% of the cells, 35% of the cells, 40% of the cells, 45% of thecells, 50% of the cells, 55% of the cells, 60% of the cells, 65% of thecells, 70% of the cells, 75% of the cells, 80% of the cells, 85% of thecells, 90% of the cell, 95% of the cells, and 100% of the cells and any% between 20% and 100% when compared to a reference cell population.

As used herein, “percent purity” or “% purity” refers to the number oftarget cells multiplied by 100 and then divided by the number ofcellular events counted, as measured on a flow cytometer, hemocytometer,coulter counter, microscopy, or other cell counting method (# of targetcells×100/# of cellular events).

As used herein, “overall percent yield” or “overall % yield” refers tothe number of target cells after a processing step times 100 and thendivided by number of target cells in the original population (# oftarget cells after a processing step×100/# of target cells in theoriginal population). The “percent yield of a processing step” or “%yield of a processing step” refers to the number of target cells after aprocessing step times 100 and then divided by number of target cells inthe preprocessed population (# of target cells after a processingstep×100/# of target cells in the preprocessed population)

As used herein, “rough sort” refers to a method of enriching ordepleting a population of cells wherein depending upon the source of theoriginal population of cells subjected to the rough sort, the resultingpopulation can contain at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%,70%, 75%, 80%, 85%, 90%, 95%, or greater of a particular cell populationcompared to the starting mixture of cells. Methods of performing a roughsort a well-known in the art and can include density separation,apheresis/leukapheresis, tetrameric antibody complex mediatedenrichment/depletion, and magnetic activated cell sorting (MACS), suchas CLINIMACS®, PRODIGY®, or EASYSEP™/ROBOSEP™.

As used herein, “fine sort” refers to a method of enriching or depletinga population of cells wherein the resulting population can contain atleast 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, orgreater of a particular cell population or populations compared to thestarting mixture of cells. Methods of performing a fine sort awell-known in the art and can include multi-parameter fluorescence basedmolecular phenotypes such as fluorescence-activated cell sorting (FACS)and microfluidics based sorting. Additional methods of performing a finesort are provided, for example, in U.S. Provisional Patent ApplicationNo. 62/421,979, which are hereby incorporated by reference in itsentirety.

As used herein, the term “binding molecule” may be any of a large numberof different molecules, or aggregates, and the terms are usedinterchangeably. Proteins, polypeptides, peptides, nucleic acids(nucleotides, oligonucleotides and polynucleotides), antibodies,saccharides, polysaccharides, lipids, receptors, test compounds(particularly those produced by combinatorial chemistry), may each or incombination (when bound to each other alone or via the target ligand) bea binding molecule.

As used herein, “specifically binds” or “specific for” refers to anassociation or union of a binding molecule (e.g., antibody) or a bindingdomain to a target (molecule or complex) with an affinity or Ka (i.e.,an equilibrium association constant of a particular binding interactionwith units of 1/M) equal to or greater than 10⁵M⁻¹ (which equals theratio of the on-rate [k_(on)] to the off-rate [k_(off)] for thisassociation reaction), while not significantly associating or unitingwith any other molecules or components in a sample. Binding molecules orbinding domains may be classified as “high affinity” binding moleculesor binding domains or as “low affinity” binding molecules or bindingdomains. “High affinity” binding molecules or binding domains refer tothose binding molecules or binding domains having a K_(a) of at least10⁷M⁻¹, at least 10⁸ M⁻¹, at least 10⁹ M⁻¹, at least 10¹⁰M⁻¹, at least10¹¹M⁻¹, at least 10¹²M⁻¹, or at least 10¹³M⁻¹. “Low affinity” bindingmolecules or binding domains refer to those binding molecules or bindingdomains having a K_(a) of up to 10⁷ M⁻¹, up to 10⁶M⁻¹, up to 10⁵M⁻¹.Alternatively, affinity may be defined as an equilibrium dissociationconstant (K_(d)) of a particular binding interaction with units of M(e.g., 10⁻⁵ M to 10⁻¹³ M).

As used herein, a “sculpted cellular graft” or “sculpted graft” refersto population of cells that has been processed from a startingpopulation of cells to provide numbers of specific cell-types within aspecified range and to reduce or remove undesired cell-types to aspecified range. Ranges are typically provided as a number of cells of aparticular variety per kg of patient body weight, but may also berepresented as a total number within the graft. A sculpted cellulargraft can comprise a mixture of cells that include target cell toaccounting cell ratios that do not occur in nature or percentagerepresentations that do not occur in nature.

As used herein, a “unit dose” of refers to specified minimum numbers,specified numbers, or ranges of populations of therapeutic cells foreach kilogram (kg) of body weight of a subject receiving a sculptedcellular graft. It is recognized that the number of unit doses variesdepending on the size of the subject. A unit dose may be divided into afraction of a unit dose depending on the weight of the subject. In someembodiments, the therapeutic cell populations (e.g., HPSC, Tmem, Treg,iNKT, etc.) may be divided into separate containers for administrationto a subject.

Therapeutic Cellular Compositions

In certain embodiments, the present disclosure provided distincttherapeutic populations of cells that form a pharmaceutical compositionuseful in hematopoietic stem/progenitor cell transplant. The therapeuticpopulation of cells can comprise an enriched population of hematopoieticstem/progenitor cells (HSPC), memory T cells (Tmem), regulatory T cells(Treg), and wherein the population of cells is depleted of naïveconventional αβ-T cells. In some embodiments, the Treg comprise naïveTreg, memory Treg, or both. In some embodiments, the Tmem comprise Tstem central memory cells (T_(SCM)), a population of T central memorycells (T_(CM)), a population of T effector memory cells (T_(EM)), or anycombination thereof. In some embodiments, the therapeutic populationincludes an enriched population of invariant Natural Killer T cells(iNKT).

In some embodiments, the therapeutic composition may comprise HSPCs andTmems. In some cases, the therapeutic composition may comprise HSPCs,Tmems and Tregs. In some cases, the therapeutic composition may compriseHSPCs and Tregs. In some cases, the therapeutic composition may compriseHSPCs and iNKT cells. In some cases, the therapeutic composition maycomprise HSPCs, Tregs, Tmems and iNKT cells.

In certain embodiments of this disclosure, the HSPC are CD34⁺. The HSPCcan be further or alternatively described as CD133⁺, CD90⁺, CD38⁻,CD45RA⁻, Lin⁻, or any combination thereof. In some embodiments, the HSPCare CD19⁻, TCRα/β⁻, or a combination thereof. In some embodiments, theTreg are CD25⁺, CD4⁺, and CD127^(−/lo) cells, or any combinationthereof. In some embodiments, the Treg are CD4⁺, CD25⁺, CD127^(−/lo),FoxP3⁺, or any combination thereof. In some embodiments, the naïve Tregare CD4⁺, CD25⁺, CD127^(−/lo), FoxP3⁺, CD45RA⁺, CD45RO⁻, or anycombination thereof. In some embodiments, the memory Treg are CD4⁺,CD25⁺, CD127^(−/lo), FoxP3⁺, CD45RA⁻, CD45RO⁺, or any combinationthereof. In some embodiments, the Tmem are CD25⁻, CD45RA⁻ cells or anycombination thereof. In some embodiments, the Tmem are CD3⁺, CD45RA⁻,CD45RO⁺, or any combination thereof. In some embodiments, the T_(SCM)are CD45RA⁺ and CD4⁺ or CD8⁺. The T_(SCM) can further be described asCD95⁺, CD122⁺, CXCR3⁺, LFA-1⁺, or any combination thereof. In someembodiments, the T_(CM) are CD45RO⁺ and CD4⁺ or CD8⁺. The T_(CM) canfurther be described as CD45RA⁻, CD62L⁺, CCR7⁺, or any combinationthereof. In some embodiments, the T_(EM) are CD4⁺, CD45RO⁺, CD45RA⁻,CD62L⁻, CCR7⁻, or any combination thereof. In some embodiments, the iNKTare CD1d-tet⁺, 6B11⁺, or both. In some embodiments, the iNKT areVα24Jα18⁺. In some embodiments, the iNKT cells may be CD25⁺, 6B11⁺,CD4⁺, Vα24Jα18⁺, CD127^(dim/−) cells or any combination thereof. In anyof the embodiments described herein, the naïve conventional αβ-T cellsare CD25⁻, CD45RA⁺ or any combination thereof. In some embodiments, thenaïve conventional αβ-T cells can be TCRα/β⁺ CD45RA⁺ and CD25⁻, CD127⁺,or both. The naïve conventional αβ-T cells can further be described asTCRα⁺ TCRβ⁺ CD45RA⁺ CD45RO⁻ CD25⁻ CD95⁻ IL-2Rβ⁻ CD127⁺ Vα24Jα18⁻.

In certain embodiments, the concentration of therapeutic cells isdescribed as a ratio of HSPC to another cell type. In some embodiments,the ratio of HSPC to Tmem comprises a range from 500:1 to 1:1,000, 400:1to 1:1,000, 300:1 to 1:1,000, 200:1 to 1:1,000, 100:1 to 1:1,000, 50:1to 1:1,000, 10:1 to 1:1,000, 5:1 to 1:1,000, 4:1 to 1:1,000, 3:1 to1:1,000, 2:1 to 1:1,000, 1:1 to 1:1,000, 500:1 to 1:900, 500:1 to 1:800,500:1 to 1:700, 500:1 to 1:600, 500:1 to 1:500, 500:1 to 1:400, 500:1 to1:300, 500:1 to 1:200, 500:1 to 1:100, 500:1 to 1:50, 500:1 to 1:20,500:1 to 1:10, 500:1 to 1:9, 500:1 to 1:8, 500:1 to 1:7, 500:1 to 1:6,500:1 to 1:5, 500:1 to 1:4, 500:1 to 1:3, 500:1 to 1:2, 500:1 to 1:1,400:1 to 1:900, 300:1 to 1:800, 200:1 to 1:700, 100:1 to 1:600, 50:1 to1:500, 10:1 to 1:400, 5:1 to 1:300, 4:1 to 1:200, 3:1 to 1:100, 2:1 to1:50, or 1:1 to 1:20.

In some embodiments, the ratio of HSPC to Tmem comprises a range from10:1 to 1:200, 100:1 to 1:2,000, or 1,000:1 to 1:20,000.

The ratio of HSPC to Treg can comprise a range from 20:1 to 1:3, 100:1to 1:30, or 200:1 to 1:300. The ratio of HSPC to naïve Treg can comprisea range from 1:500 to 100:1, 1:400 to 100:1, 1:300 to 100:1, 1:200 to100:1, 1:100 to 100:1, 1:50 to 100:1, 1:20 to 100:1, 1:10 to 100:1, 1:5to 100:1, 1:1 to 100:1, 1:200 to 50:1, 1:200 to 20:1, 1:200 to 10:1,1:200 to 5:1, 1:100 to 1:1, 40:1 to 1:3, 200:1 to 1:15, or 400:1 to1:150. The ratio of HSPC to Memory Treg can comprise a range from 1:500to 10,000:1, 1:400 to 10,000:1, 1:300 to 10,000:1, 1:200 to 10,000:1,1:100 to 10,000:1, 1:50 to 10,000:1, 1:20 to 10,000:1, 1:10 to 10,000:1,1:5 to 10,000:1, 1:1 to 10,000:1, 1:500 to 5,000:1, 1:500 to 1,000:1,1:500 to 900:1, 1:500 to 800:1, 1:500 to 700:1, 1:500 to 600:1, 1:500 to500:1, 1:500 to 400:1, 1:500 to 300:1, 1:500 to 200:1, 1:500 to 100:1,1:500 to 50:1, 1:500 to 20:1, 1:500 to 10:1, 1:500 to 5:1, or 1:500 to1:1.

The ratio of HSPC to iNKT can comprise a range from 1:2 to 1,000,000:1,1:2 to 500,000:1, 1:1 to 500,000:1, 100:1 to 1,000,000:1, 100:1 to500,000:1, 100:1 to 100,000:1, 500:1 to 1,000,000:1, 500:1 to 500,000:1,500:1 to 100,000:1, 1,000:1 to 100,000:1, 1,000:1 to 1,000,000:1,1,000:1 to 500,000:1, 1,000:1 to 100,000:1, 10,000:1 to 1:2,100,000:1-1:20, or 1,000,000:1-1:200.

In certain embodiments, the concentration of therapeutic cells isdescribed as a ratio of naïve conventional αβ-T cells to a therapeuticcell type. The ratio of naïve conventional αβ-T cells to HSPC can beless than 1:3, less than 1:50, less than 1:100, less than 1:200, lessthan 1:300, less than 1:400. less than 1:500, less than 1:600, less than1:700, less than 1:800, less than 1:900, less than 1:1,000, less than1:1,500, less than 1:2,000, less than 1:3,000, less than 1:4,000, lessthan 1:5,000, less than 1:6,000, less than 1:7,000, less than 1:8,000,less than 1:9,000, less than 1:10,000, less than 1:50,000, less than1:100,000, less than 1:200,000, less than 1:300,000, less than1:400,000, less than 1:500,000, less than 1:600,000, less than1:700,000, less than 1:800,000, less than 1:900,000, less than1:1,000,000.

The ratio of naïve conventional αβ-T cells to Tmem can be less than1:30, less than 1:200, less than 1:300, less than 1:400, less than1:500, less than 1:600, less than 1:700, less than 1:800, less than1:900, less than 1:1000, less than 1:5000, less than 1:10000, less than1:15000, less than 1:20000, less than 1:25000, less than 1:30000, lessthan 1:35000, less than 1:40000, less than 1:45000, or less than1:50000.

The ratio of naïve conventional αβ-T cells to Treg can be less than 1:1,less than 1:2, less than 1:3, less than 1:4, less than 1:5, less than1:6, less than 1:7, less than 1:8, less than 1:9, 1:10, less than 1:15,less than 1:20, less than 1:30, less than 1:200, less than 1:300, lessthan 1:400, less than 1:500, less than 1:600, less than 1:700, less than1:800, less than 1:900, less than 1:1000, less than 1:5000, less than1:10000, less than 1:15000, less than 1:20000, less than 1:25000, lessthan 1:30000, less than 1:35000, less than 1:40000, less than 1:45000,or less than 1:50000. The ratio of naïve conventional αβ-T cells tonaïve Treg can be less than 1:1, less than 1:2, less than 1:3, less than1:4, less than 1:5, less than 1:6, less than 1:7, less than 1:8, lessthan 1:9, 1:10, less than 1:15, less than 1:20, less than 1:30, lessthan 1:200, less than 1:300, less than 1:400, less than 1:500, less than1:600, less than 1:700, less than 1:800, less than 1:900, less than1:1000, less than 1:5000, less than 1:10000, less than 1:15000, lessthan 1:20000, less than 1:25000, less than 1:30000, less than 1:35000,less than 1:40000, less than 1:45000, or less than 1:50000. The ratio ofnaïve conventional αβ-T cells to Memory Treg can be less than 1:1, lessthan 1:2, less than 1:3, less than 1:4, less than 1:5, less than 1:6,less than 1:7, less than 1:8, less than 1:9, less than 1:10, less than1:15, less than 1:20, less than 1:30, less than 1:200, less than 1:300,less than 1:400, less than 1:500, less than 1:600, less than 1:700, lessthan 1:800, less than 1:900, less than 1:1000, less than 1:5000, lessthan 1:10000, less than 1:15000, less than 1:20000, less than 1:25000,less than 1:30000, less than 1:35000, less than 1:40000, less than1:45000, or less than 1:50000.

The ratio of naïve conventional αβ-T cells to iNKT can be less than100:1, less than 1:1, less than 1:2, less than 1:3, less than 1:4, lessthan 1:5, less than 1:6, less than 1:7, less than 1:8, less than 1:9,less than 1:10, less than 1:15, less than 1:20, less than 1:30, lessthan 1:200, less than 1:300, less than 1:400, less than 1:500, less than1:600, less than 1:700, less than 1:800, less than 1:900, less than1:1000, less than 1:5000, less than 1:10000, less than 1:15000, lessthan 1:20000, less than 1:25000, less than 1:30000, less than 1:35000,less than 1:40000, less than 1:45000, less than 1:50000.

In some embodiments of the instant disclosure, the ratio of Tmem to Tregis not dependent on the concentration of starting cells (e.g.substantially modified from the starting concentrations). This providesan advantage because the concentration of Tmem can be controlled (e.g.dose escalated) independent of the concentration of Treg. The ratio ofTmem to Treg can be from 30:1 to 1:1, 25:1 to 1:1, 20:1 to 1:1, 15:1 to1:1, 10:1 to 1:1, 9:1 to 1:1, 8:1 to 1:1, 7:1 to 1:1, 6:1 to 1:1, 5:1 to1:1, 4:1 to 1:1, 3:1 to 1:1, 2:1 to 1:1. In certain embodiments, theratio of Tmem to Treg can be from 1:1 to 200:1, 1:10 to 2000:1, or 1:100to 20,000:1. The ratio of Tmem to naïve Treg can be from 5:1 to 1:10,3:1 to 1:10, 3:1 to 1:10, 2:1 to 1:10, or 1:1 to 1:10. The ratio of Tmemto memory Treg can be from 27:1 to 0.9:1, 30:1 to 1:10, 25:1 to 1:10,20:1 to 1:10, 15:1 to 1:10, 10:1 to 1:10, 30:1 to 1:9, 30:1 to 1:8, 30:1to 1:7, 30:1 to 1:6, 30:1 to 1:5, 30:1 to 1:4, 30:1 to 1:3, 30:1 to 1:2,or 30:1 to 1:1.

In some embodiments of the instant disclosure, the ratio of Treg to iNKTcan be from 20,000:1 to 1:5, 200,000:1 to 1:50, or 2,000,000:1 to 1:500.

In some embodiments of the instant disclosure, the ratio of iNKT to Tmemcan be from 2:1 to 1:100,000, 5:1 to 1:1,000,000, or 10:1 to1:10,000,000.

In some embodiments, the number of naïve conventional αβ-T cells in acomposition can be less than about 2%, 5%, 7%, 10%, 12%, 15%, 17%, 20%,25%, 27%, 30%, 32% or 35% of the number of HSPCs. In some embodiments,the number of naïve conventional αβ-T cells in a composition can beabout 2%, 5%, 7%, 10%, 12%, 15%, 17%, 20%, 25%, 27%, 30%, 32% or 35% ofthe number of HSPCs. In some embodiments, the number of naïveconventional αβ-T cells in a composition can be about 2% to about 7%,about 2% to about 10%, about 2% to about 15%, about 2% to about 20%,about 2% to about 25%, about 2% to about 30%, about 2% to about 35%,about 7% to about 10%, about 7% to about 15%, about 7% to about 20%,about 7% to about 25%, about 7% to about 30%, about 7% to about 35%,about 10% to about 15%, about 10% to about 20%, about 10% to about 25%,about 10% to about 30%, about 10% to about 35%, about 15% to about 20%,about 15% to about 25%, about 15% to about 30%, about 15% to about 35%,about 20% to about 25%, about 20% to about 30%, about 20% to about 35%,about 25% to about 30%, about 25% to about 35%, or about 30% to about35% of the number of HSPCs.

In some embodiments, the number of naïve conventional αβ-T cells in acomposition can be less than about 0.1%, 1%, 2%, 5%, 7%, 10%, 12%, 15%,17%, 20%, 22% or 25% of the number of Tmem cells. In some embodiments,the number of naïve conventional αβ-T cells in a composition can be atmost about 20%. In some embodiments, the number of naïve conventionalαβ-T cells in a composition can be about 0.1% to about 2%, about 0.1% toabout 5%, about 0.1% to about 10%, about 0.1% to about 15%, about 0.1%to about 20%, about 2% to about 5%, about 2% to about 10%, about 2% toabout 15%, about 2% to about 20%, about 5% to about 10%, about 5% toabout 15%, about 5% to about 20%, about 10% to about 15%, about 10% toabout 20%, or about 15% to about 20% of the number of Tmem cells.

In some embodiments, the number of naïve conventional αβ-T cells in acomposition can be less than about 0.05%, 0.5%, 1%, 2%, 5%, 7%, 10%,12%, 15%, 17%, 20%, 22%, 25% or 30% of the number of Treg cells. In someembodiments, the number of naïve conventional αβ-T cells in acomposition can be about 0.05% to about 1%, about 0.05% to about 5%,about 0.05% to about 10%, about 0.05% to about 15%, about 0.05% to about20%, about 0.05% to about 30%, about 1% to about 5%, about 1% to about10%, about 1% to about 15%, about 1% to about 20%, about 1% to about30%, about 5% to about 10%, about 5% to about 15%, about 5% to about20%, about 5% to about 30%, about 10% to about 15%, about 10% to about20%, about 10% to about 30%, about 15% to about 20%, about 15% to about30%, or about 20% to about 30% of the number of Treg cells.

In some embodiments, the number of naïve conventional αβ-T cells in acomposition can be less than about 1%, 10%, 20%, 50%, 70%, 80% or 90% ofthe number of iNKT cells. In some embodiments, the number of naïveconventional αβ-T cells in a composition can be about 1% to about 10%,about 1% to about 20%, about 1% to about 50%, about 1% to about 70%,about 1% to about 80%, about 1% to about 90%, about 10% to about 20%,about 10% to about 50%, about 10% to about 70%, about 10% to about 80%,about 10% to about 90%, about 20% to about 50%, about 20% to about 70%,about 20% to about 80%, about 20% to about 90%, about 50% to about 70%,about 50% to about 80%, about 50% to about 90%, about 70% to about 80%,about 70% to about 90%, or about 80% to about 90% of the number of iNKTcells.

In certain embodiments, the population of therapeutic cells comprises10% to 65% HSPC. In certain embodiments, the population of therapeuticcells comprises 2% to 20% Treg. In certain embodiments, the populationof therapeutic cells comprises 25% to 90% Tmem. In certain embodiments,the population of therapeutic cells comprises less than 2% naïveconventional αβ-T cells. In certain embodiments, the population oftherapeutic cells comprises: 10% to 65% HSPC; 2% to 20% Treg; 25% to 90%Tmem; and less than 2% naïve conventional αβ-T cells. In someembodiments, the population of Treg comprises 2% to 5%, 2% to 10%, 2% to20%, 2% to 30%, 2% to 40%, 2% to 50%, 5% to 10%, 5% to 20%, 5% to 30%,5% to 40%, 5% to 50%, 10% to 20%, 10% to 30%, 10% to 40%, 10% to 50%,15% to 20%, 15% to 30%, 15% to 40%, or 15% to 50% naïve Treg. In someembodiments, the population of Treg comprises 75% to 95% memory Treg. Insome embodiments, the population of naïve T cells comprises 0.1% to 10%T_(SCM). In some embodiments, the population of Tmem comprises 0% to 99%T_(CM). In some embodiments, the population of Tmem comprises 0% to 99%T_(EM). In certain embodiments, the population further comprises 0.01%to 5%, 0.05% to 5%, 0.1% to 5%, 0.5% to 5%, 1% to 5%, 0.01% to 1.5%,0.05% to 1.5%, 0.1% to 1.5%, 0.5% to 1.5%, or 1% to 1.5% iNKT.

In any of the embodiments disclosed herein, the cell population can beprovided by processing a sample from one or more tissue harvests. Insome embodiments, a the sample or tissue harvest is from a single donor.The one or more tissue harvests can be from one or more donors. Forexample, the tissue harvest can be from an HLA matched sibling donor, anHLA matched unrelated donor, a partially matched unrelated donor, ahaploidentical related donor, autologous donor, a full HLA mismatchallogeneic donor, a pool of donors, or any combination thereof.

In any of the embodiments disclosed herein, the cell population can be aformulation for administration to a subject. In some cases, cellpopulations may be formulated using excipients. In some embodiments, thecells are formulated for infusion or injection. The excipients cancomprise Normosol-R and human serum. The human serum can be 0.2% of thetotal formulation. The human serum can be 0.5% of the total formulation.The human serum can be 1% of the total formulation. The human serum canbe 2% of the total formulation. In addition, the formulation cancomprise a pH buffer, such as 0.1 mM-100 mM phosphate pH 6.0-9.0,0.1-100 mM HEPES pH 6.0-9.0, 0.1 mM-100 mM bicarbonate pH 6.0-9.0, 0.1mM-100 mM citrate pH 6.0-9.0, 0.1-100 mM acetate pH 4.0-8.0 or anycombination thereof. The formulation can comprise electrolytes, such as5 mM-400 mM NaCl, 0.5 mM-50 mM KCl, 0.05 mM-50 mM CaCl2, 0.05 mM-50 mMMgCl2, 0.05 mM-50 mM LiCl2, 0.05 mM-50 mM MnCl2, or any combinationthereof. The formulation can comprise an energy source, such as 0.1mM-100 mM glucose, 0.1 mM-100 mM pyruvate, 0.1 mM-100 mM fructose,0.1-100 mM sucrose, 0.1-50 mM glycerol, 0.1 mM-100 mM gluconolactone,0.1-100 mM gluconate or any combination thereof. The formulation cancomprise an anti-oxidant, such as 0.05-10 mM glutathione (reduced),0.05-10 mM glutathione (oxidized), 0.001 mM-10 mM β-mercaptoethanol.0.001 mM-10 mM dithiothreitol, 0.01-100 mM ascorbate, 0.001-10 mMtris(2-carboxyethyl)phosphine, or any combination thereof. Theformulation can comprise a stabilizer, such as 0.01%-10% human serumalbumin, 0.01%-10% bovine serum albumin, 0.1%-99% human serum, 0.1%-99%fetal bovine serum, 0.01%-10% IgG, 0.1%-10% immunoglobin, 0.06%-60%trehalose, or molecular polymers like 0.1%-20% polyethylene glycocol (MW200-20,000,000), or any combination thereof.

In some embodiments disclosed herein, the cell population formulated foradministration to a subject based on the weight of the subject (e.g.,number of cells/kg of subject weight). The cell population may beformulated as a pharmaceutical composition. In some embodiments, thepharmaceutical composition comprises a unit dose of a cellular graft(e.g. the cell population), wherein each unit dose of the cellular graftcomprises populations of therapeutic cells for each kilogram (kg) ofbody weight of a subject receiving the cellular graft. In someembodiments, the population or unit dose of cells comprises about 1×10⁶HSPCs to about 20×10⁶ HSPCs per kg of the subject. In some embodiments,the population or unit dose of cells comprises at least about 1×10⁶HSPCs per kg of the subject. In some embodiments, the population or unitdose of cells comprises at most about 20×10⁶ HSPCs per kg of thesubject. In some embodiments, the population or unit dose comprises arange of HSPC cells from about 0.5×10⁶ to 50×10⁶, 1.0×10⁶ to 20×10⁶, or2.0×10⁶ to 10×10⁶ cells/kg of subject weight.

In some embodiments, the population or unit dose of cells comprisesabout 1×10⁶ HSPCs to about 2×10⁶ HSPCs, about 1×10⁶ HSPCs to about 5×10⁶HSPCs, about 1×10⁶ HSPCs to about 7×10⁶ HSPCs, about 1×10⁶ HSPCs toabout 10×10⁶ HSPCs, about 1×10⁶ HSPCs to about 15×10⁶ HSPCs, about 1×10⁶HSPCs to about 20×10⁶ HSPCs, about 2×10⁶ HSPCs to about 5×10⁶ HSPCs,about 2×10⁶ HSPCs to about 7×10⁶ HSPCs, about 2×10⁶ HSPCs to about10×10⁶ HSPCs, about 2×10⁶ HSPCs to about 15×10⁶ HSPCs, about 2×10⁶ HSPCsto about 20×10⁶ HSPCs, about 5×10⁶ HSPCs to about 7×10⁶ HSPCs, about5×10⁶ HSPCs to about 10×10⁶ HSPCs, about 5×10⁶ HSPCs to about 15×10⁶HSPCs, about 5×10⁶ HSPCs to about 20×10⁶ HSPCs, about 7×10⁶ HSPCs toabout 10×10⁶ HSPCs, about 7×10⁶ HSPCs to about 15×10⁶ HSPCs, about 7×10⁶HSPCs to about 20×10⁶ HSPCs, about 10×10⁶ HSPCs to about 15×10⁶ HSPCs,about 10×10⁶ HSPCs to about 20×10⁶ HSPCs, or about 15×10⁶ HSPCs to about20×10⁶ HSPCs per kg of the subject. In some embodiments, the populationof cells comprises about 1×10⁶ HSPCs, about 2×10⁶ HSPCs, about 5×10⁶HSPCs, about 7×10⁶ HSPCs, about 10×10⁶ HSPCs, about 15×10⁶ HSPCs, orabout 20×10⁶ HSPCs per kg of the subject.

In some embodiments, the population or unit dose of cells comprisesabout 1×10⁶ Tmem cells to about 100×10⁶ Tmem cells per kg of thesubject. In some embodiments, the population or unit dose of cellscomprises at least about 1×10⁶ Tmem cells per kg of the subject. In someembodiments, the population or unit dose of cells comprises at mostabout 100×10⁶ Tmem cells per kg of the subject. In some embodiments, thepopulation or unit dose of cells comprises about 1×10⁶ Tmem cells toabout 10×10⁶ Tmem cells, about 1×10⁶ Tmem cells to about 20×10⁶ Tmemcells, about 1×10⁶ Tmem cells to about 50×10⁶ Tmem cells, about 1×10⁶Tmem cells to about 75×10⁶ Tmem cells, about 1×10⁶ Tmem cells to about100×10⁶ Tmem cells, about 10×10⁶ Tmem cells to about 20×10⁶ Tmem cells,about 10×10⁶ Tmem cells to about 50×10⁶ Tmem cells, about 10×10⁶ Tmemcells to about 75×10⁶ Tmem cells, about 10×10⁶ Tmem cells to about100×10⁶ Tmem cells, about 20×10⁶ Tmem cells to about 50×10⁶ Tmem cells,about 20×10⁶ Tmem cells to about 75×10⁶ Tmem cells, about 20×10⁶ Tmemcells to about 100×10⁶ Tmem cells, about 50×10⁶ Tmem cells to about75×10⁶ Tmem cells, about 50×10⁶ Tmem cells to about 100×10⁶ Tmem cells,or about 75×10⁶ Tmem cells to about 100×10⁶ Tmem cells per kg of thesubject. In some embodiments, the population or unit dose of cellscomprises about 1×10⁶ Tmem cells, about 10×10⁶ Tmem cells, about 20×10⁶Tmem cells, about 50×10⁶ Tmem cells, about 75×10⁶ Tmem cells, or about100×10⁶ Tmem cells per kg of the subject.

In some embodiments, the population or unit dose of cells comprisesabout 0.5×10⁶ Treg cells to about 2.5×10⁶ Treg cells per kg of thesubject. In some embodiments, the population or unit dose of cellscomprises at least about 0.5×10⁶ Treg cells per kg of the subject. Insome embodiments, the population or unit dose of cells comprises at mostabout 2.5×10⁶ Treg cells per kg of the subject. In some embodiments, thepopulation or unit dose of cells comprises about 0.5×10⁶ Treg cells toabout 1×10⁶ Treg cells, about 0.5×10⁶ Treg cells to about 1.5×10⁶ Tregcells, about 0.5×10⁶ Treg cells to about 2×10⁶ Treg cells, about 0.5×10⁶Treg cells to about 2.5×10⁶ Treg cells, about 1×10⁶ Treg cells to about1.5×10⁶ Treg cells, about 1×10⁶ Treg cells to about 2×10⁶ Treg cells,about 1×10⁶ Treg cells to about 2.5×10⁶ Treg cells, about 1.5×10⁶ Tregcells to about 2×10⁶ Treg cells, about 1.5×10⁶ Treg cells to about2.5×10⁶ Treg cells, or about 2×10⁶ Treg cells to about 2.5×10⁶ Tregcells per kg of the subject. In some embodiments, the population or unitdose of cells comprises about 0.5×10⁶ Treg cells, about 1×10⁶ Tregcells, about 1.5×10⁶ Treg cells, about 2×10⁶ Treg cells, or about2.5×10⁶ Treg cells per kg of the subject. In some embodiments, thepopulation or unit dose of cells comprises a range of naïve Treg fromabout 0.1×10⁶ to about 500×10⁶, about 0.2×10⁶ to about 500×10⁶, about0.3×10⁶ to about 500×10⁶, about 0.4×10⁶ to about 500×10⁶, about 0.5×10⁶to about 500×10⁶, about 0.6×10⁶ to about 500×10⁶, about 0.7×10⁶ to about500×10⁶, about 0.8×10⁶ to about 500×10⁶, about 0.9×10⁶ to about 500×10⁶,or about 1×10⁶ to about 500×10⁶ cells/kg of subject weight. In someembodiments, the population or unit dose of cells comprises a range ofMemory Treg from 0.005×10⁶ to 500×10⁶ cells/kg of subject weight.

In some embodiments, the population or unit dose of cells comprises arange of iNKT cells from 0.5×10³ to 2000×10³ cells/kg of subject weight,0.5×10³ to 1×10⁷ cells/kg of subject weight, or 1.0×10⁴ to 2.5×10⁶cells/kg of subject weight. In some embodiments, the population or unitdose of cells comprises about 0.01×10⁶ iNKT cells to about 3×10⁶ iNKTcells per kg of the subject. In some embodiments, the population or unitdose of cells comprises at least about 0.01×10⁶ iNKT cells per kg of thesubject. In some embodiments, the population or unit dose of cellscomprises at most about 3×10⁶ iNKT cells per kg of the subject. In someembodiments, the population or unit dose of cells comprises about0.01×10⁶ iNKT cells to about 0.1×10⁶ iNKT cells, about 0.01×10⁶ iNKTcells to about 1×10⁶ iNKT cells, about 0.01×10⁶ iNKT cells to about1.5×10⁶ iNKT cells, about 0.01×10⁶ iNKT cells to about 2×10⁶ iNKT cells,about 0.01×10⁶ iNKT cells to about 3×10⁶ iNKT cells, about 0.1×10⁶ iNKTcells to about 1×10⁶ iNKT cells, about 0.1×10⁶ iNKT cells to about1.5×10⁶ iNKT cells, about 0.1×10⁶ iNKT cells to about 2×10⁶ iNKT cells,about 0.1×10⁶ iNKT cells to about 3×10⁶ iNKT cells, about 1×10⁶ iNKTcells to about 1.5×10⁶ iNKT cells, about 1×10⁶ iNKT cells to about 2×10⁶iNKT cells, about 1×10⁶ iNKT cells to about 3×10⁶ iNKT cells, about1.5×10⁶ iNKT cells to about 2×10⁶ iNKT cells, about 1.5×10⁶ iNKT cellsto about 3×10⁶ iNKT cells, or about 2×10⁶ iNKT cells to about 3×10⁶ iNKTcells per kg of the subject. In some embodiments, the population or unitdose of cells comprises about 0.01×10⁶ iNKT cells, about 0.1×10⁶ iNKTcells, about 1×10⁶ iNKT cells, about 1.5×10⁶ iNKT cells, about 2×10⁶iNKT cells, or about 3×10⁶ iNKT cells per kg of the subject.

In some embodiments, the population or unit dose of cells comprises arange of naïve conventional αβ-T cells less than 1×10⁶ cells/kg ofsubject weight. In some embodiments, the population or unit dose ofcells comprises a range of naïve conventional αβ-T cells less than 3×10⁵cells/kg of subject weight. In some embodiments, the population or unitdose of cells comprises a range of naïve conventional αβ-T cells lessthan 7.5×10⁴ cells/kg of subject weight, less than 5×10⁴ cells/kg, lessthan 1×10⁴ cells/kg, less than 0.5×10⁴ cells/kg, or less than 1×10³cells/kg of subject weight.

In some embodiments, the populations of therapeutic cells of each unitdose comprise: 1.0×10⁶ to 50×10⁶ hematopoietic stem/progenitor cells(HSPC), 0.1×10⁶ to 1000×10⁶ memory T cells (Tmem), 0.1×10⁶ to 1000×10⁶regulatory T cells (Treg), and of less than 3×10⁵ naïve conventionalαβ-T. In some embodiments, the populations of therapeutic cells of eachunit dose comprise: 3.0×10⁶ to 50×10⁶ hematopoietic stem/progenitorcells (HSPC), 0.3×10⁶ to 1000×10⁶ memory T cells (Tmem), 0.5×10⁶ to1000×10⁶ regulatory T cells (Treg), and of less than 3×10⁵ naïveconventional αβ-T. In some embodiments, the populations of therapeuticcells of each unit dose comprise: 1.0×10⁶ to 50×10⁶ hematopoieticstem/progenitor cells (HSPC), 0.3×10⁶ to 1000×10⁶ memory T cells (Tmem),0.5×10⁶ to 1000×10⁶ regulatory T cells (Treg), and less than 3×10⁵ naïveconventional αβ-T.

In any one of the embodiments disclosed herein, the HSPC can be providedby a donor that is haploidentical to the subject. In some embodiments,the Treg, Tmem, iNKT, or any combination thereof are provided by a donorthat is an HLA matched sibling donor or an HLA matched unrelated donoror partially matched HLA unrelated donor. In some embodiments, the HSPCare provided by a donor that is haploidentical to the subject and theTreg, Tmem, iNKT, or any combination thereof are provided by a donorthat is an HLA matched sibling donor or an HLA matched unrelated donor.

Methods of Treatment

The present disclosure provides methods of performing cellular grafttherapy in a subject having a disease, condition, or disordercomprising: administering any of the therapeutic cellular graftcompositions described herein to the subject. For example, a therapeuticcomposition comprising cells can be infused to a subject in needthereof.

Subjects that can be treated include subjects afflicted with leukemia,lymphoma, chronic infection, or autoimmune disease, malignant ornonmalignant blood disease, AML, ALL, CML, CLL, Multiple Myeloma,Hodgkin's lymphoma, non-Hodgkin's lymphoma, MDS, Lymphoproliferativediseases, type 1 diabetes, inborn errors of metabolism, genetic disease,severe combined immunodeficiency, sickle cell anemia, beta-thallasemia,multiple sclerosis, solid organ transplantation, Crohn's disease,ulcerative colitis, lupus, Hemophagocytic lymphohistiocytosis, glycogenstorage disorders, breast cancer, other solid tumors, leukodystrophies,mucopolysaccharidosis or any other disease that would benefit from aHSPC transplant. In some embodiments, the subject is afflicted with ALLor AML in relapse or with primary refractory ALL or AML with less than10% blasts. In some embodiments, the subject is afflicted with high riskAML in ≥CR1 or with minimal residual disease positivity. In someembodiments, the subject is afflicted with high risk ALL in >=CR1 orwith minimal residual disease positivity. In some embodiments, thesubject is afflicted with high risk CML. In some embodiments, thesubject is afflicted with high risk myeloproliferative disorders. Insome embodiments, the subject is afflicted with relapsed non-Hodgkinlymphoma responsive to therapy. In some embodiments, the subject isafflicted with MDS with blast count less than 10% blasts at the time oftransplantation. In certain embodiments, the subject has one or more ofthe following characteristics: age 18-65, Karnofsky score≥60 or ECOG≤2,HCT-Comorbidity Index≤4, Creatinine<1.5 mg/dL, Cardiac ejectionfraction>45%, DLCO corrected>60% of predicted, total bilirubin<3 timesupper limit of normal (ULN) (unless attributed to Gilbert syndrome), ASTand ALT<3 times ULN, not pregnant or nursing, HIV negative, and noco-existing disease that would limit life expectancy to <6 months. Incertain embodiments, the subject has one or more of the followingcharacteristics: age patients 0-3, 3-6, 6-12, 12-14, 12-18, 18-65,65-70, 70-75, 75-80, 80-90 or older, or any range in between, Karnofskyscore≥60 or ≥80, or ECOG≤2, HCT-Comorbidity Index≤4, Creatinine<1.5mg/dL, Cardiac ejection fraction>45%, DLCO corrected>60% of predicted,total bilirubin<3 times upper limit or <1.5 times upper limit of normal(ULN) (unless attributed to Gilbert syndrome), AST and ALT<3 times or<1.5 times the ULN, not pregnant or nursing, HIV negative, and noco-existing disease that would limit life expectancy to <6 months.

Therapeutic cellular compositions described herein can be administeredin place of traditional HCT. Exemplary therapeutic cellular compositionsare compatible with reduced intensity conditioning (RIC) andmyeloablative (MA) regimens. Because of the reduced risk of GVHD, MAconditioning may be used in place of RIC for some patients, especiallythose with underlying malignancies. Because the therapeutic cellularcompositions disclosed here have decreased GVHD, the alloreactivity maybe beneficial in the case of multiple myeloma, where GVHD risks outweighalloreactivity and auto transplant is clinically used currently.Non-malignant conditions are likely to benefit from increased immunereconstitution and therefore lower rates of infection and higher ratesof engraftment and durable chimerism.

Therapeutic cellular compositions described herein are administered tosubjects in accordance with known techniques, or variations thereof thatwill be apparent to those skilled in the art.

An “effective amount” or “therapeutically effective amount” refers tothat amount of a composition described herein which, when administeredto a subject (e.g., human), is sufficient to aid in treating a disease.The amount of a composition that constitutes a “therapeuticallyeffective amount” will vary depending on the cell preparations, thecondition and its severity, the manner of administration, and the age ofthe subject to be treated, but can be determined routinely by one ofordinary skill in the art having regard to his own knowledge and to thisdisclosure. When referring to an individual active ingredient orcomposition, administered alone, a therapeutically effective dose refersto that ingredient or composition alone. When referring to acombination, a therapeutically effective dose refers to combined amountsof the active ingredients, compositions or both that result in thetherapeutic effect, whether administered serially, concurrently orsimultaneously.

In some embodiments, the HSPC cells are administered at a concentrationof CD34⁺ cells 1.0×10⁶ to 50×10⁶ cells/kg of subject weight, 1.0×10⁶ to20×10⁶ cells/kg of subject weight, or 2.0×10⁶ to 10×10⁶ cells/kg ofsubject weight. In some embodiments, the HSPC cells are administered ata concentration of about 1×10⁶ HSPCs to about 20×10⁶ HSPCs per kg of thesubject. In some embodiments, the HSPC cells are administered at aconcentration of at least about 1×10⁶ HSPCs per kg of the subject. Insome embodiments, the HSPC cells are administered at a concentration ofat most about 20×10⁶ HSPCs per kg of the subject. In some embodiments,the HSPC cells are administered at a concentration of about 1×10⁶ HSPCsto about 2×10⁶ HSPCs, about 1×10⁶ HSPCs to about 5×10⁶ HSPCs, about1×10⁶ HSPCs to about 7×10⁶ HSPCs, about 1×10⁶ HSPCs to about 10×10⁶HSPCs, about 1×10⁶ HSPCs to about 15×10⁶ HSPCs, about 1×10⁶ HSPCs toabout 20×10⁶ HSPCs, about 2×10⁶ HSPCs to about 5×10⁶ HSPCs, about 2×10⁶HSPCs to about 7×10⁶ HSPCs, about 2×10⁶ HSPCs to about 10×10⁶ HSPCs,about 2×10⁶ HSPCs to about 15×10⁶ HSPCs, about 2×10⁶ HSPCs to about20×10⁶ HSPCs, about 5×10⁶ HSPCs to about 7×10⁶ HSPCs, about 5×10⁶ HSPCsto about 10×10⁶ HSPCs, about 5×10⁶ HSPCs to about 15×10⁶ HSPCs, about5×10⁶ HSPCs to about 20×10⁶ HSPCs, about 7×10⁶ HSPCs to about 10×10⁶HSPCs, about 7×10⁶ HSPCs to about 15×10⁶ HSPCs, about 7×10⁶ HSPCs toabout 20×10⁶ HSPCs, about 10×10⁶ HSPCs to about 15×10⁶ HSPCs, about10×10⁶ HSPCs to about 20×10⁶ HSPCs, or about 15×10⁶ HSPCs to about20×10⁶ HSPCs per kg of the subject. In some embodiments, the HSPC cellsare administered at a concentration of about 1×10⁶ HSPCs, about 2×10⁶HSPCs, about 5×10⁶ HSPCs, about 7×10⁶ HSPCs, about 10×10⁶ HSPCs, about15×10⁶ HSPCs, or about 20×10⁶ HSPCs per kg of the subject.

In some embodiments, the Tmem are administered at a concentration of0.1×10⁶ to 1000×10⁶ cells/kg of subject weight, 1.0×10⁶ to 250×10⁶cells/kg of subject weight, or 2.9×10⁶ to 10.1×10⁶ cells/kg of subjectweight, 10.1×10⁶ to 30.1×10⁶ cells/kg of subject weight, 30.1×10⁶ to101×10⁶ cells/kg of subject weight, 1.0×10⁶ to 100×10⁶ cells/kg ofsubject weight. In some embodiments, the Tmem cells are administered ata concentration of about 1×10⁶ Tmem cells to about 100×10⁶ Tmem cellsper kg of the subject. In some embodiments, the Tmem cells areadministered at a concentration of at least about 1×10⁶ Tmem cells perkg of the subject. In some embodiments, the Tmem cells are administeredat a concentration of at most about 100×10⁶ Tmem cells per kg of thesubject. In some embodiments, the Tmem cells are administered at aconcentration of about 1×10⁶ Tmem cells to about 10×10⁶ Tmem cells,about 1×10⁶ Tmem cells to about 20×10⁶ Tmem cells, about 1×10⁶ Tmemcells to about 50×10⁶ Tmem cells, about 1×10⁶ Tmem cells to about 75×10⁶Tmem cells, about 1×10⁶ Tmem cells to about 100×10⁶ Tmem cells, about10×10⁶ Tmem cells to about 20×10⁶ Tmem cells, about 10×10⁶ Tmem cells toabout 50×10⁶ Tmem cells, about 10×10⁶ Tmem cells to about 75×10⁶ Tmemcells, about 10×10⁶ Tmem cells to about 100×10⁶ Tmem cells, about 20×10⁶Tmem cells to about 50×10⁶ Tmem cells, about 20×10⁶ Tmem cells to about75×10⁶ Tmem cells, about 20×10⁶ Tmem cells to about 100×10⁶ Tmem cells,about 50×10⁶ Tmem cells to about 75×10⁶ Tmem cells, about 50×10⁶ Tmemcells to about 100×10⁶ Tmem cells, or about 75×10⁶ Tmem cells to about100×10⁶ Tmem cells per kg of the subject. In some embodiments, the Tmemcells are administered at a concentration of about 1×10⁶ Tmem cells,about 10×10⁶ Tmem cells, about 20×10⁶ Tmem cells, about 50×10⁶ Tmemcells, about 75×10⁶ Tmem cells, or about 100×10⁶ Tmem cells per kg ofthe subject.

In some embodiments, the Treg are administered at a concentration of0.1×10⁶ to 1000×10⁶ cells/kg of subject weight, 0.1×10⁶ to 5×10⁶cells/kg of subject weight, or 0.5×10⁶ to 2.5×10⁶ cells/kg of subjectweight. In some embodiments, the Treg are administered at aconcentration of about 0.5×10⁶ Treg cells to about 2.5×10⁶ Treg cellsper kg of the subject. In some embodiments, the Treg are administered ata concentration of at least about 0.5×10⁶ Treg cells per kg of thesubject. In some embodiments, the Treg are administered at aconcentration of at most about 2.5×10⁶ Treg cells per kg of the subject.In some embodiments, the Treg are administered at a concentration ofabout 0.5×10⁶ Treg cells to about 1×10⁶ Treg cells, about 0.5×10⁶ Tregcells to about 1.5×10⁶ Treg cells, about 0.5×10⁶ Treg cells to about2×10⁶ Treg cells, about 0.5×10⁶ Treg cells to about 2.5×10⁶ Treg cells,about 1×10⁶ Treg cells to about 1.5×10⁶ Treg cells, about 1×10⁶ Tregcells to about 2×10⁶ Treg cells, about 1×10⁶ Treg cells to about 2.5×10⁶Treg cells, about 1.5×10⁶ Treg cells to about 2×10⁶ Treg cells, about1.5×10⁶ Treg cells to about 2.5×10⁶ Treg cells, or about 2×10⁶ Tregcells to about 2.5×10⁶ Treg cells per kg of the subject. In someembodiments, the Treg are administered at a concentration of about0.5×10⁶ Treg cells, about 1×10⁶ Treg cells, about 1.5×10⁶ Treg cells,about 2×10⁶ Treg cells, or about 2.5×10⁶ Treg cells per kg of thesubject.

In some embodiments, the naïve Treg are administered at a concentrationof about 0.1×10⁶ to about 500×10⁶, about 0.2×10⁶ to about 500×10⁶, about0.3×10⁶ to about 500×10⁶, about 0.4×10⁶ to about 500×10⁶, about 0.5×10⁶to about 500×10⁶, about 0.6×10⁶ to about 500×10⁶, about 0.7×10⁶ to about500×10⁶, about 0.8×10⁶ to about 500×10⁶, about 0.9×10⁶ to about 500×10⁶,or about 1×10⁶ to about 500×10⁶ cells/kg of subject weight

In some embodiments, the memory Treg are administered at a concentrationof 0.005×10⁶ to 500×10⁶ cells/kg of subject weight.

In some embodiments, the iNKT cells are administered at a concentrationof 0.5×10² to 2000×10³ cells/kg of subject weight, 0.5×10² to 1×10⁴cells/kg of subject weight, 0.5×10³ to 1×10⁵ cells/kg of subject weight,0.5×10⁴ to 1×10⁶ cells/kg of subject weight, 0.5×10⁵ to 1×10⁷ cells/kgof subject weight 0.5×10² to 1×10⁷ cells/kg of subject weight, or1.0×10⁴ to 2.5×10⁶ cells/kg of subject weight. In some embodiments, theiNKT cells are administered at a concentration of about 0.01×10⁶ iNKTcells to about 3×10⁶ iNKT cells per kg of the subject. In someembodiments, the iNKT cells are administered at a concentration of atleast about 0.01×10⁶ iNKT cells per kg of the subject. In someembodiments, the iNKT cells are administered at a concentration of atmost about 3×10⁶ iNKT cells per kg of the subject. In some embodiments,the iNKT cells are administered at a concentration of about 0.01×10⁶iNKT cells to about 0.1×10⁶ iNKT cells, about 0.01×10⁶ iNKT cells toabout 1×10⁶ iNKT cells, about 0.01×10⁶ iNKT cells to about 1.5×10⁶ iNKTcells, about 0.01×10⁶ iNKT cells to about 2×10⁶ iNKT cells, about0.01×10⁶ iNKT cells to about 3×10⁶ iNKT cells, about 0.1×10⁶ iNKT cellsto about 1×10⁶ iNKT cells, about 0.1×10⁶ iNKT cells to about 1.5×10⁶iNKT cells, about 0.1×10⁶ iNKT cells to about 2×10⁶ iNKT cells, about0.1×10⁶ iNKT cells to about 3×10⁶ iNKT cells, about 1×10⁶ iNKT cells toabout 1.5×10⁶ iNKT cells, about 1×10⁶ iNKT cells to about 2×10⁶ iNKTcells, about 1×10⁶ iNKT cells to about 3×10⁶ iNKT cells, about 1.5×10⁶iNKT cells to about 2×10⁶ iNKT cells, about 1.5×10⁶ iNKT cells to about3×10⁶ iNKT cells, or about 2×10⁶ iNKT cells to about 3×10⁶ iNKT cellsper kg of the subject. In some embodiments, the iNKT cells areadministered at a concentration of about 0.01×10⁶ iNKT cells, about0.1×10⁶ iNKT cells, about 1×10⁶ iNKT cells, about 1.5×10⁶ iNKT cells,about 2×10⁶ iNKT cells, or about 3×10⁶ iNKT cells per kg of the subject.

In some embodiments, the administered cells comprise naïve conventionalαβ-T cells at less than 3×10⁵ cells/kg of subject weight. In someembodiments, the administered cells comprise naïve conventional αβ-Tcells less than 2×10⁵ cells/kg of subject weight, less than 1×10⁵cells/kg of subject, weight less than 7.5×10⁴ cells/kg, less than 5×10⁴cells/kg, less than 1×10⁴ cells/kg, less than 0.5×10⁴ cells/kg or lessthan 1×10³ cells/kg of subject weight.

As further discussed in the Examples, the purity of the therapeuticcellular composition can be important to the clinical outcome of thetreatment. For example, processing of cellular fractions that mayinclude naïve Tcon contaminating cells with therapeutic cells usingmethod that results in low purity can impair the therapeutic efficacy byresulting higher levels of GVHD, acute GVHD grades 3-4, steroidresistant acute GVHD grades 3-4, chronic GVHD, graft failure, graftrejection, serious infection, organ failure, VOD/SOS, and relapsecompared to therapeutic cellular compositions prepared using highfidelity sorting techniques (e.g. FACS).

Without wishing to be bound by theory, it is believed that thetherapeutic cellular compositions disclosed herein provide a superiortherapeutic benefit in myeloablative transplant procedures because theTreg, Tmem, and iNKT cells that are provided with the HSPCs result inearly rescue of the subject's immune system compared to traditionalmyeloablative HSPC transplant procedures. When a subject receives atraditional myeloablative HSPC transplant, the immune system can take upto a year to begin to significantly recover and provide protectiveimmunity. In comparison, it is thought the introduction of Treg, Tmem,or iNKT cells with HSPCs in the presently disclosed therapeuticcomposition provide a supplement to the subject's ablated immune cells.These supplemented cells begin to provide significant immune functionshortly after administration. Therefore, the presently disclosedtherapeutic cellular composition provides a superior therapeutic benefitcompared to traditional HSPC transplants. It is also believed thatregulatory T cells may assist in engraftment and preventing GVHD bysuppressing alloreactive T cells in solid tissue. It is also thoughtthat iNKT cells supply Tregs with positive feedback signals to promote asuppressive environment especially in solid tissues. It is also thoughtthat HSPC will reconstitute the blood and immune system of amyeloablated patient, including reconstitution of NK cells, which arefurther thought to provide a graft versus leukemia effect. It is alsothought that the memory T cells provide anti-infection effects andanti-leukemia effects for a limited time (less than 5 years). Because oftheir limited lifetime, these cells cannot sustain a prolonged graftversus host disease reaction.

In some embodiments, the therapeutic cell populations are administeredto the subject as separate pharmaceutical compositions. For example, theenriched HSPC, Tmem, Treg or iNKT cell populations may be administeredsequentially. In some embodiments, the therapeutic cell populations areadministered in multiple doses. In some cases, a dose of the cellpopulations may comprise HSPCs. In some cases, a dose of the cellpopulations may comprise Treg cells. In some cases, a dose of the cellpopulations may comprise Tmem cells. In some cases, a dose of the cellpopulations may comprise iNKT cells. In some embodiments, thetherapeutic cell populations are administered simultaneously to thesubject as a single pharmaceutical composition. The doses may beadministered as a course of therapy. A course of therapy my compriseadministering a dose to a subject at 1 day, 2 day, 3 day, 4 day, 5 day,6 day, 7 day intervals. A course of therapy my comprise administering adose to a subject at 1 week, 2 week, 3 week, or 4 week intervals. Acourse of therapy my comprise administering a dose to a subject at 1month, 2 month, 3 month, or 4 month intervals.

In some embodiments, the therapeutic compositions described herein maybe administered as separate populations of cells. For instance, a firstdose of a therapeutic composition can comprise administering any of apopulation of HSPCs, a population of Treg cells, or a population of Tmemcells, alone or in any combination. A subsequent dose can then compriseany of the above cell types not present in the first dose. A dose alsocan comprise iNKT cells. By way of example, a first dose can compriseHSPCs, while a second dose comprises Treg and Tmem cells. Othercombinations of doses may also be administered to a subject.

In some embodiments, a complete dose of the therapeutic composition maycomprise a plurality of doses. A complete therapeutic compositiondescribed herein may be administered in at least 1 dose. A completetherapeutic composition described herein may be administered in at most30 doses. In some cases, a complete therapeutic composition describedherein may be administered in about 2 doses, 5 doses, 10 doses, 15doses, 20 doses, 25 doses or 30 doses. In some cases, a dose of thecomplete therapeutic composition may comprise HSPCs, Treg cells, Tmemcells. In some cases, individual doses of the complete therapeuticcomposition may comprise different cell populations.

In some embodiments, a unit dose may comprise at least 3×10⁵ HSPCs perkg of a subject. In some embodiments, a unit dose may comprise at least3×10⁵ Treg cells per kg of a subject. In some embodiments, a unit dosemay comprise at least 3×10⁵ Tmem cells per kg of a subject. In someembodiments, a unit dose may comprise at least 3×10⁵ iNKT cells per kgof a subject. In some embodiments, a unit dose may comprise less than3×10⁵ Tcon cells per kg of a subject.

In some embodiments, the complete therapeutic composition may beadministered in about 1 day. In some cases, the complete therapeuticcomposition may be administered in at most 30 days. For instance, afirst dose of the therapeutic compositions described herein may beadministered in 1 day and a second dose is administered after 10 days.In some cases, the complete therapeutic composition may be administeredin about 1 day, 2 days, 5 days, 10 days, 15 days, 20 days or 30 days.

In some embodiments, the cells are isolated from a donor that is an HLAmatched sibling donor, an HLA matched unrelated donor, a partiallymatched unrelated donor, a haploidentical related donor, autologousdonor, an HLA unmatched donor, a pool of donors or any combinationthereof. In some embodiments, the population of therapeutic cells isallogeneic. In some embodiments, the population of therapeutic cells isautologous. In some embodiments, the population of therapeutic cells ishaploidentical. In some embodiments, the population of therapeutic cellsis isolated from mobilized peripheral blood, mobilized apheresisproduct, bone marrow, umbilical cord blood, non-mobilized blood,non-mobilized apheresis product, or any combination thereof.

In some embodiments, the population of therapeutic cells is derived froma single tissue harvest. In some embodiments, the population oftherapeutic cells is derived from one or more tissue harvest. In someembodiments, the population of therapeutic cells comprises HSPC providedby at least a first donor and Treg and Tmem provided by at least asecond donor. In some embodiments, the population of therapeutic cellscomprises iNKT cells provided by at least the second donor. In certainembodiments, the first donor is haploidentical to the subject. Incertain embodiments, the second donor is an HLA matched sibling donor oran HLA matched or partially matched unrelated donor.

In some embodiments, the subject has been conditioned with radiation,chemotherapy, recombinant proteins, antibodies, or toxin-conjugatedantibodies, or any combination thereof prior to treatment. In someembodiments, the subject is conditioned for cellular graft therapy byfirst treating the subject with myeloablative therapy. Exemplarymyeloablative therapies include chemotherapy or radiotherapy.Myleoablative therapies are thought to provide therapeutic benefit bydebulking the tumor. Cancer cells are generally more susceptible tochemotherapy/radiotherapy than many normal cells. However, iftumor-initiating cell survives a course of chemotherapy/radiotherapy,then the subject risks relapse. Therefore, high levels of chemotherapycan help improve the elimination of tumor-initiating populations;however, at these concentrations toxicity occurs against normal cells.Though some of the susceptible normal cells are non-essential,hematopoietic stem cells are killed to a lethal extent by high levels ofchemotherapy. Myeloablative regimens eradicate a sufficient amount ofHSCs that the patient would otherwise die without a transplant. WhenHSPCs are infused into the myeloablated subject, the donor cells canrescue the subject and reconstitute the blood and the immune system ofthe subject for life. In some embodiments, the myeloablative therapycomprises administration of busulfan, cyclophosphamide, TBI,fludarabine, etoposide, or any combination thereof. In some embodiments,the myeloablative therapy comprises administration an anti-cKITantibody. In some embodiments, the myeloablative therapy comprisesadministration an antibody drug conjugate. The antibody drug conjugatecan be, for example, anti-CD45-saporin or anti-cKit-saporin therapeuticantibodies. In some embodiments, the myeloablative therapy is a reducedintensity conditioning therapy.

In certain embodiments, therapeutic cell populations are administered tothe subject as combination therapy comprising immunosuppressive agents.Exemplary immunosuppressive agents include sirolimus, tacrolimus,cyclosporine, mycophenolate, anti-thymocyte globulin, corticosteroids,calcineurin inhibitor, anti-metabolite, such as methotrexate,post-transplant cyclophosphamide or any combination thereof. In someembodiments, the subject is pretreated with only sirolimus or tacrolimusas prohpylaxis against GVHD. In some embodiments, the therapeutic cellpopulations are administered to the subject before an immunosuppressiveagent. In some embodiments, the therapeutic cell populations areadministered to the subject after an immunosuppressive agent. In someembodiments, the therapeutic cell populations are administered to thesubject at the concurrently with an immunosuppressive agent. In someembodiments, the therapeutic cell populations are administered to thesubject without an immunosuppressive agent. In some embodiments, thepatient receiving a therapeutic cell population is receivesimmunosuppressive agent for less than 6 months, 5 months, 4 months, 3months, 2 months, 1 month, 3 weeks, 2 weeks, or 1 week.

In some embodiments, a subject is receiving Bu/Flu and/or Bu/Cy startsTacrolimus at day +3 at an initial dose of 0.03 mg/kg/day intravenousinfusion with a target of 4-8 ng/ml. In some embodiments, a subject isreceiving Cy/TBI (Also for TBI/VP-16 or TBI/VP-16/Cy) starts Sirolimusat day +3 at an initial dose of 6 mg loading dose followed by 2 mg dailywith a target of 3-8 ng/ml. Should a subject become intolerant of theirspecific GVHD prophylaxis or other reasons to change are determined bythe treating physician then prophylaxis can be altered at the discretionof the treating physician, with the recommendation that Tacrolimus,Sirolimus or Mycophenolate Mofetil be utilized. Should GVHD occur, theappropriate treatment schedule and dose will be initiated. Recipientswho develop acute GVHD will be treated at the discretion of the treatingphysician.

Selection and Sorting of Cell Populations

Prior to formulation or administration of the therapeutic cells, asource(s) of cells is obtained from donor (e.g., peripheral bloodmononuclear cells, bone marrow, umbilical cord blood), from whichtherapeutic cells are enriched or depleted. Methods for enriching ordepleting of specific subset cell populations in a mixture of cells arewell known in the art. For example, cell populations can be enriched ordepleted by density separation, rosetting tetrameric antibody complexmediated enrichment/depletion, magnetic activated cell sorting (MACS),multi-parameter fluorescence based molecular phenotypes such asfluorescence-activated cell sorting (FACS), or any combination thereof.Additional methods of enriching or depleting cell populations areprovided, for example, U.S. Provisional Application 62/421,979; U.S.Patent Application Publication No. 2014/0011690; and U.S. PatentApplication Publication No. 2016/0245805, which are hereby incorporatedby reference in their entirety. Collectively, these methods of enrichingor depleting cell populations may be referred to generally herein as“sorting” the cell populations or contacting the cells “underconditions” to form or produce an enriched (+) or depleted (−) cellpopulation.

Accordingly, embodiments of the instant disclosure includes methods forproducing a pharmaceutical composition comprising, processing at leastone sample to provide: (a) a population of enriched hematopoieticstem/progenitor cells (HSPC); (b) a population of enriched regulatory Tcells (Treg); (c) a population of enriched memory T cells (Tmem); and(d) formulating the enriched HSPC, memory T cells, and Treg populationsas a pharmaceutical composition suitable for administration to asubject, wherein the populations of (a)-(c) are depleted of naïveconventional αβ-T cells. In some embodiments, the method can furthercomprise processing the sample to provide a population of enriched iNKTcells.

In some embodiments, the method further comprises processing the sampleto provide a population of cells depleted of Lin⁺ cells. The method cancomprise providing a population of enriched naïve Treg, a population ofenriched memory Treg, or both. In some embodiments, providing thepopulation of enriched Tmem comprises providing a population of enrichedT stem central memory cells (T_(SCM)), a population of enriched Tcentral memory cells (T_(CM)), a population of enriched T effectormemory cells (T_(EM)), or any combination thereof. In some embodiments,the method can further comprise processing the sample to provide apopulation of enriched iNKT cells.

In some embodiments, the population of enriched HSPC comprises at least50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%,96%, 97%, 98%, or 99% or more CD34⁺ HSPC. In some embodiments, thepopulation of cells depleted of Lin⁺ cells comprises 1%-30% Lin⁺ cells,preferably less than 1% Lin⁺ cells. In some embodiments, the populationof enriched Treg comprises 20%-99.9% Treg. In some embodiments, thepopulation of enriched Tmem comprises 10%-99.9% Tmem. In someembodiments, the population of enriched iNKT comprises 10%-99.9% iNKT.

In some embodiments, formulating the pharmaceutical compositioncomprises combining the enriched HSPC population, memory T cellspopulations, Treg populations, iNKT population, or any combinationthereof into a mixed population of enriched cells.

In some embodiments, the mixed population of enriched cells comprises aratio of HSPC to Tmem comprises a range from 500:1 to 1:1,000, 400:1 to1:1,000, 300:1 to 1:1,000, 200:1 to 1:1,000, 100:1 to 1:1,000, 50:1 to1:1,000, 10:1 to 1:1,000, 5:1 to 1:1,000, 4:1 to 1:1,000, 3:1 to1:1,000, 2:1 to 1:1,000, 1:1 to 1:1,000, 500:1 to 1:900, 500:1 to 1:800,500:1 to 1:700, 500:1 to 1:600, 500:1 to 1:500, 500:1 to 1:400, 500:1 to1:300, 500:1 to 1:200, 500:1 to 1:100, 500:1 to 1:50, 500:1 to 1:20,500:1 to 1:10, 500:1 to 1:9, 500:1 to 1:8, 500:1 to 1:7, 500:1 to 1:6,500:1 to 1:5, 500:1 to 1:4, 500:1 to 1:3, 500:1 to 1:2, 500:1 to 1:1,400:1 to 1:900, 300:1 to 1:800, 200:1 to 1:700, 100:1 to 1:600, 50:1 to1:500, 10:1 to 1:400, 5:1 to 1:300, 4:1 to 1:200, 3:1 to 1:100, 2:1 to1:50, or 1:1 to 1:20. In some embodiments, the mixed population ofenriched cells comprises a ratio of HSPC to Tmem comprises a range from10:1 to 1:200, 100:1 to 1:2,000, or 1,000:1 to 1:20,000.

In some embodiments, the mixed population of enriched cells comprises aratio of HSPC to Treg can comprise a range from 20:1 to 1:3, 100:1 to1:30, or 200:1 to 1:300. The ratio of HSPC to naïve Treg can comprise arange from 1:500 to 100:1, 1:400 to 100:1, 1:300 to 100:1, 1:200 to100:1, 1:100 to 100:1, 1:50 to 100:1, 1:20 to 100:1, 1:10 to 100:1, 1:5to 100:1, 1:1 to 100:1, 1:200 to 50:1, 1:200 to 20:1, 1:200 to 10:1,1:200 to 5:1, 1:100 to 1:1, 40:1 to 1:3, 200:1 to 1:15, or 400:1 to1:150.

In some embodiments, the mixed population of enriched cells comprises aratio of HSPC to Memory Treg can comprise a range from 1:500 to10,000:1, 1:400 to 10,000:1, 1:300 to 10,000:1, 1:200 to 10,000:1, 1:100to 10,000:1, 1:50 to 10,000:1, 1:20 to 10,000:1, 1:10 to 10,000:1, 1:5to 10,000:1, 1:1 to 10,000:1, 1:500 to 5,000:1, 1:500 to 1,000:1, 1:500to 900:1, 1:500 to 800:1, 1:500 to 700:1, 1:500 to 600:1, 1:500 to500:1, 1:500 to 400:1, 1:500 to 300:1, 1:500 to 200:1, 1:500 to 100:1,1:500 to 50:1, 1:500 to 20:1, 1:500 to 10:1, 1:500 to 5:1, or 1:500 to1:1.

In some embodiments, the mixed population of enriched cells comprises aratio of HSPC to iNKT can comprise a range from 1:2 to 1,000,000:1, 1:2to 500,000:1, 1:1 to 500,000:1, 100:1 to 1,000,000:1, 100:1 to500,000:1, 100:1 to 100,000:1, 500:1 to 1,000,000:1, 500:1 to 500,000:1,500:1 to 100,000:1, 1,000:1 to 100,000:1, 1,000:1 to 1,000,000:1,1,000:1 to 500,000:1, 1,000:1 to 100,000:1, 10,000:1 to 1:2,100,000:1-1:20, or 1,000,000:1-1:200.

In some embodiments, the mixed population of enriched cells comprises aratio of naïve conventional αβ-T cells to HSPC less than 1:3, less than1:50, less than 1:100, less than 1:200, less than 1:300, less than1:400. less than 1:500, less than 1:600, less than 1:700, less than1:800, less than 1:900, less than 1:1,000, less than 1:1,500, less than1:2,000, less than 1:3,000, less than 1:4,000, less than 1:5,000, lessthan 1:6,000, less than 1:7,000, less than 1:8,000, less than 1:9,000,less than 1:10,000, less than 1:50,000, less than 1:100,000, less than1:200,000, less than 1:300,000, less than 1:400,000, less than1:500,000, less than 1:600,000, less than 1:700,000, less than1:800,000, less than 1:900,000, or less than 1:1,000,000.

In some embodiments, the mixed population of enriched cells comprises aratio of naïve conventional αβ-T cells to Tmem can be less than 1:30,less than 1:200, less than 1:300, less than 1:400, less than 1:500, lessthan 1:600, less than 1:700, less than 1:800, less than 1:900, less than1:1000, less than 1:5000, less than 1:10000, less than 1:15000, lessthan 1:20000, less than 1:25000, less than 1:30000, less than 1:35000,less than 1:40000, less than 1:45000, or less than 1:50000.

The ratio of naïve conventional αβ-T cells to Treg can be less than 1:1,1:10, less than 1:30, less than 1:200, less than 1:300, less than 1:400,less than 1:500, less than 1:600, less than 1:700, less than 1:800, lessthan 1:900, less than 1:1000, less than 1:5000, less than 1:10000, lessthan 1:15000, less than 1:20000, less than 1:25000, less than 1:30000,less than 1:35000, less than 1:40000, less than 1:45000, or less than1:50000. The ratio of naïve conventional αβ-T cells to naïve Treg can beless than 1:1, 1:10, less than 1:30, less than 1:200, less than 1:300,less than 1:400, less than 1:500, less than 1:600, less than 1:700, lessthan 1:800, less than 1:900, less than 1:1000, less than 1:5000, lessthan 1:10000, less than 1:15000, less than 1:20000, less than 1:25000,less than 1:30000, less than 1:35000, less than 1:40000, less than1:45000, or less than 1:50000. The ratio of naïve conventional αβ-Tcells to Memory Treg can be less than 1:1, less than 1:2, less than 1:3,less than 1:4, less than 1:5, less than 1:6, less than 1:7, less than1:8, less than 1:9, less than 1:10, less than 1:15, less than 1:20, lessthan 1:30, less than 1:200, less than 1:300, less than 1:400, less than1:500, less than 1:600, less than 1:700, less than 1:800, less than1:900, less than 1:1000, less than 1:5000, less than 1:10000, less than1:15000, less than 1:20000, less than 1:25000, less than 1:30000, lessthan 1:35000, less than 1:40000, less than 1:45000, or less than1:50000. The ratio of naïve conventional αβ-T cells to iNKT can be lessthan 100:1, less than 1:1, less than 1:2, less than 1:3, less than 1:4,less than 1:5, less than 1:6, less than 1:7, less than 1:8, less than1:9, less than 1:10, less than 1:15, less than 1:20, less than 1:30,less than 1:200, less than 1:300, less than 1:400, less than 1:500, lessthan 1:600, less than 1:700, less than 1:800, less than 1:900, less than1:1000, less than 1:5000, less than 1:10000, less than 1:15000, lessthan 1:20000, less than 1:25000, less than 1:30000, less than 1:35000,less than 1:40000, less than 1:45000, less than 1:50000.

In some embodiments of the instant disclosure, the ratio of Tmem to Tregis not dependent on the concentration of starting cells (e.g.substantially modified from the starting concentrations). This providesan advantage because the concentration of Tmem can be controlled (e.g.dose escalated) independent of the concentration of Treg. The ratio ofTmem to Treg can be from 30:1 to 1:1, 25:1 to 1:1, 20:1 to 1:1, 15:1 to1:1, 10:1 to 1:1, 9:1 to 1:1, 8:1 to 1:1, 7:1 to 1:1, 6:1 to 1:1, 5:1 to1:1, 4:1 to 1:1, 3:1 to 1:1, 2:1 to 1:1. In certain embodiments, theratio of Tmem to Treg can be from 1:1 to 200:1, 1:10 to 2000:1, or 1:100to 20,000:1. The ratio of Tmem to naïve Treg can be from 5:1 to 1:10,3:1 to 1:10, 3:1 to 1:10, 2:1 to 1:10, or 1:1 to 1:10. The ratio of Tmemto memory Treg can be from 27:1 to 0.9:1, 30:1 to 1:10, 25:1 to 1:10,20:1 to 1:10, 15:1 to 1:10, 10:1 to 1:10, 30:1 to 1:9, 30:1 to 1:8, 30:1to 1:7, 30:1 to 1:6, 30:1 to 1:5, 30:1 to 1:4, 30:1 to 1:3, 30:1 to 1:2,or 30:1 to 1:1.

In some embodiments of the instant disclosure, the ratio of Treg to iNKTcan be from 20,000:1 to 1:5, 200,000:1 to 1:50, or 2,000,000:1 to 1:500.

In some embodiments of the instant disclosure, the ratio of iNKT to Tmemcan be from 2:1 to 1:100,000, 5:1 to 1:1,000,000, or 10:1 to1:10,000,000.

In some embodiments, the HSPC are CD34⁺. The HSPC can further bedescribed as CD133⁺, CD90⁺, CD38⁻, CD45RA⁻, Lin⁻, or any combinationthereof. In some embodiments, the HSPC are CD19⁻, TCRα/β⁻, or acombination thereof. In some embodiments, the Lin⁺ cells express CD19,CD11c, CD66B, CD14, CD20, or any combination thereof. In someembodiments, the Treg are CD4⁺, CD25⁺, CD127^(−/lo), FoxP3⁺, or anycombination thereof. In some embodiments, the naïve Treg are CD4⁺,CD25⁺, CD127^(−/lo), FoxP3⁺, CD45RA⁺, CD45RO⁻, or any combinationthereof. In some embodiments, the memory Treg are CD4⁺, CD25⁺,CD127^(−/lo), FoxP3⁺, CD45RA⁻, CD45RO⁺, or any combination thereof. Insome embodiments, the Tmem are CD3⁺, CD45RA⁻, CD45RO⁺, or anycombination thereof. In some embodiments, the T_(SCM) are CD45RA⁺ andCD4⁺ or CD8⁺. The T_(SCM) can further be described as CD95⁺, CD122⁺,CXCR3⁺, LFA-1⁺, or any combination thereof. In some embodiments, theT_(CM) are CD45RO⁺ and CD4⁺ or CD8⁺. The T_(CM) can further be describedas CD45RA⁻, CD62L⁺, CCR7⁺, or any combination thereof. In someembodiments, the T_(EM) are CD4⁺, CD45RO⁺, CD45RA⁻, CD62L⁻, CCR7⁻, orany combination thereof. In some embodiments, the iNKT are CD1d-tet⁺,6B11⁺, Vα24Jα18⁺ or any combination thereof. In any of the embodimentsdescribed herein, the naïve conventional αβ-T cells are TCRα/β⁺ CD45RA⁺and CD25⁻, CD127⁺, or both. The naïve conventional αβ-T cells canfurther be described as TCRα⁺ TCRβ⁺ CD45RA⁺ CD45RO⁻ CD25⁻ CD95⁻ CD127⁺.

In some embodiments, a biological sample may be sorted to isolatepopulations of interest such as HSPCs, Treg cells, Tmem cells or acombination thereof. In some cases, a biological sample may be contactedwith a molecule that specifically binds CD34 for isolation of HSPCs. Thesample may be enriched for CD34⁺ to yield a CD34⁺ cell population and aCD34⁻ cell population. In some cases, the CD34⁻ cell population may becontacted with a molecule that specifically binds CD25. The sample maythen be enriched for CD25⁺ cells by sorting the CD34⁻ cell populationfor a CD25⁺ cell population, thereby yielding a CD34⁻ CD25⁻ cellpopulation and a CD34⁻ CD25⁺ cell population. The CD34⁻ CD25⁺ cellpopulation may be further sorted to yield a Treg cell population. TheCD34⁻ CD25⁺ cells may be contacted with a molecule that specificallybinds CD4 and a molecule that specifically binds CD127. The cells maythen be sorted to yield a CD34⁻ CD25⁺ CD4⁺ CD127^(dim/−) Treg cellpopulation. In some cases, the CD34⁻ CD25⁻ cell population may befurther sorted to enrich Tmem cells. The cells may be contacted with amolecule that specifically binds CD45RA. The cell sample may be sortedto yield a CD34⁻ CD25⁻ CD45RA⁻ Tmem cell population. The CD45RA⁻ naïveconventional αβ-T cells may be discarded for the depletion of naïveconventional αβ-T cells.

In some embodiments, a biological sample may be sorted to isolatepopulations of interest such as HSPCs, Treg cells, Tmem cells, iNKTcells or a combination thereof. In some cases, a biological sample maybe contacted with a molecule that specifically binds CD34 for isolationof HSPCs. The sample may be enriched for CD34⁺ to yield a CD34⁺ cellpopulation and a CD34⁻ cell population. In some cases, the CD34⁻ cellpopulation may be contacted with a molecule that specifically binds CD25and a molecule that specifically binds 6B11. The sample may then beenriched for CD25⁺ and 6B11⁺ cells by sorting the CD34⁻ cell populationfor a CD25⁺ cell population, thereby yielding a CD34⁻CD25⁻ 6B11⁻ cellpopulation and a CD34⁻CD25⁺ 6B11⁺ cell population. The CD34⁻ CD25⁺6B11⁺cell population may be further sorted to yield a Treg and iNKT cellpopulation. The CD34⁻ CD25⁺ 6B11⁺ cells may be contacted with a moleculethat specifically binds CD4 and with a molecule that specifically bindsCD127. The cells may then be sorted to yield a CD34⁻CD25⁺6B11⁺ CD4⁺CD127^(dim/−) Treg cell population. In some cases, the CD34⁻ CD25⁻6B11⁻cell population may be further sorted to enrich Tmem cells. The cellsmay be contacted with a molecule that specifically binds CD45RA. Thecell sample may be sorted to yield a CD34⁻ CD25⁻6B11⁻CD45RA⁻ Tmem cellpopulation. The CD45RA⁺ naïve conventional αβ-T cells may be discardedfor the depletion of naïve conventional αβ-T cells. In some embodiments,the method of producing the therapeutic compositions described hereinmay comprise separately sorting different populations of cells. Forinstance, HSPCs, Treg cells, Tmem cells and/or iNKT cells may be sortedseparately. The separately sorted populations may be mixed to form atherapeutic composition. In some cases, the separate populations ofcells may be isolated from different donors. For instance, HSPCs may beisolated from donor 1 and Treg and Tmem cells may be sorted from donor2. Alternatively, all cell populations may be isolated from the samedonor. In some embodiments, the sample comprises mobilized peripheralblood, mobilized apheresis product, bone marrow, umbilical cord blood,non-mobilized blood, non-mobilized apheresis product, or any combinationthereof. In some embodiments, the sample comprises cultured cellsderived from PBMCs. In some embodiments, the sample comprises culturedcells derived from induced pluripotent stem cells (iPSC). In someembodiments, the sample is prepared for processing a density gradient,Ficoll, Percoll, red blood cell hypotonic lysis,Ammonium-Chloride-Potassium (ACK) buffer, or any combination thereof. Insome embodiments, the sample is provided by a single tissue harvest. Insome embodiments, the sample is provided by one or more tissue harvests.

Example Sort Scheme 1

In certain embodiments, the methods for producing a pharmaceuticalcomposition comprise: A. contacting the sample with a molecule thatspecifically binds CD34 under conditions to form a population of CD34⁺cells and a population of CD34⁻ cells, recovering the population ofCD34⁺ cells from the sample, and recovering the population of CD34⁻cells from the sample; and B. processing the population of CD34⁻ cellsto provide least one population of enriched therapeutic cells comprisingTreg, Tmem, iNKT, or any combination thereof (see FIGS. 1A and B). Insome embodiments, step B comprises performing a fine sort to provide thepopulation of enriched therapeutic cells (see FIG. 1A). For example,step B can comprise contacting the population of CD34⁻ cells with amolecule that specifically binds CD45RA, a molecule that specificallybinds CD45RO, a molecule that specifically binds CD4, a molecule thatspecifically binds CD8, a molecule that specifically binds CD25, amolecule that specifically binds CD127, a CD1d-tet, a 6B11 monoclonalantibody or functional fragment thereof, or any combination thereof.

In certain embodiments, step B comprises: i. contacting the populationof CD34⁻ cells with at least one molecule that specifically binds CD45RAunder conditions to form a population of CD45RA⁺ cells and a populationof CD45RA⁻ cells, and recovering the population of CD45RA⁻ cells; andii. performing a fine sort to provide the population of enrichedtherapeutic cells from the population of CD45RA⁺ cells. The fine sortcan comprise contacting the population of CD45RA⁺ cells with a moleculethat specifically binds CD4, a molecule that specifically binds CD8, amolecule that specifically binds CD25, a molecule that specificallybinds CD127, a CD1d-tet, a 6B11 monoclonal antibody or functionalfragment thereof, or any combination thereof. The fine sort can furthercomprise contacting the population of CD45RA⁻ cells with a molecule thatspecifically binds CD45RA, a molecule that specifically binds CD45RO, ora combination thereof.

In certain embodiments, step B comprises: i. contacting the populationof CD34⁻ cells with at least one binding molecule that specificallybinds a Lin⁺ marker under conditions to form a population of Lin⁺ cellsand a population of Lin⁻ cells, and recovering the population of Lin⁻cells; and ii. performing a fine sort to provide the population ofenriched therapeutic cells from the population of Lin⁻ cells. In someembodiments, the fine sort comprises contacting the population of Lin⁻cells with a molecule that specifically binds CD45RA, a molecule thatspecifically binds CD45RO, a molecule that specifically binds CD4, amolecule that specifically binds CD8, a molecule that specifically bindsCD25, a molecule that specifically binds CD127, a CD1d-tet molecule, a6B11 monoclonal antibody or functional fragment thereof, or anycombination thereof.

In certain embodiments, step B comprises: i. contacting the populationof CD34⁻ cells with at least one binding molecule that specificallybinds at least one Lin⁺ marker under conditions to form a population ofLin⁺ cells and a population of Lin⁻ cells, and recovering the populationof Lin⁻ cells; and ii. contacting the population of Lin⁻ cells with abinding molecule that specifically binds CD25 under conditions to form apopulation of CD25⁺ cells and a population of CD25⁻ cells, recoveringthe population CD25⁺ cells, thereby producing a population of cellscomprising Treg, and recovering the population of CD25⁻ cells; and iii.contacting the population of CD25⁻ cells with a binding molecule thatspecifically binds CD45RA under conditions to form a population ofCD45RA⁺ cells and a population of CD45RA⁻ cells, and recovering thepopulation of CD45RA⁻ cells (see FIG. 1A). In some embodiments, step ii.further comprises contacting the Lin⁻ cells with CD1d-tet, a 6B11monoclonal antibody or functional fragment thereof, or a combinationthereof under conditions to form a population of CD1d-tet⁺ cells, apopulation of 6B11⁺ cells, or a combination thereof and a population ofCD1d-tet⁻ cells, 6B11⁻ cells, or a combination thereof, and recoveringthe population of CD1d-tet⁺ cells. In some embodiments, the populationof CD25⁺ cells and the population of CD1d-tet⁺ cells, 6B11⁺ cell or bothare recovered simultaneously. In some embodiments, the method furthercomprises performing a fine sort of the population of CD25⁺ cells ofstep ii. to provide a population of naïve Treg cells, a population ofmemory Treg cells, a population of iNKT cells, or any combinationthereof. In some embodiments, the population of CD45RA⁺ cells isrecovered and further performing a fine sort to provide a population ofTreg, iNKT, or both.

Example Sort Scheme 2

In certain embodiments, the methods for producing a pharmaceuticalcomposition comprise: A. performing a first rough sort on at least afirst sample, thereby providing an enriched population of CD34⁺ cells;B. performing a second rough sort on a second sample, thereby providinga population of Lin⁻ cells; C. performing a third rough sort on thepopulation of Lin⁻ cells, thereby providing a population of CD45RA⁻memory T cells and providing a population of CD45RA⁺ cells; and D.performing a fine sort on the population of CD45RA⁺ cells, therebyproviding a population of Treg (see FIGS. 2 and 3).

In some embodiments, the second sample comprises a population of CD34⁻cells recovered from step A (see FIG. 3). In some embodiments, the firstsample comprises at least one haploidentical sample (see FIG. 2A). Insome embodiments, the first sample comprises at least two haploidenticalsamples (see FIG. 2B). In some embodiments, the first sample comprisesmobilized peripheral blood, mobilized apheresis product, bone marrow,umbilical cord blood, non-mobilized blood, non-mobilized apheresisproduct, or any combination thereof. In some embodiments, the secondsample comprises peripheral blood mononuclear cells (PBMC), mobilizedperipheral blood, mobilized apheresis product, bone marrow, umbilicalcord blood, non-mobilized blood, non-mobilized apheresis product, or anycombination thereof. In some embodiments, the first sample or the secondsample is allogeneic, autologous, or a combination thereof. In someembodiments, the second sample is from an HLA matched unrelated donor, aHLA matched sibling donor, or a combination thereof (see FIGS. 2A & B).

In some embodiments, the first, second, or third rough sort comprisesdensity separation, tetrameric antibody complex mediatedenrichment/depletion, magnetic activated cell sorting, apheresis,leukapheresis, or any combination thereof.

In some embodiments, the fine sort can comprise purification usingmulti-parameter fluorescence-based molecular phenotypes. The fine sortcan provide a population of naïve Treg cells, a population of memoryTreg cells, a population of iNKT cells, or any combination thereof. Thefine sorting can comprise contacting the CD45RA⁺ cells with a bindingmolecule that specifically binds CD25 under conditions to provide apopulation of CD25⁺ cells and a population of CD25⁻ cells, andrecovering a population of CD25⁺ cells, thereby providing a populationof Treg. In some embodiments, the population of CD25⁺ cells is furthersorted under conditions to provide a population of naïve Treg cells. Insome embodiments, the fine sort comprises contacting the CD45RA⁺ cellswith a CD1d-tet, 6B11 monoclonal antibody or functional fragmentthereof, or a combination thereof under conditions to provide apopulation of CD1d-tet⁺ cells, 6B11⁺ cells, or both, and recovering thepopulation of CD1d-tet⁺ cells, 6B11⁺ cells, or both.

Example Sort Scheme 3

In certain embodiments, the methods for producing a pharmaceuticalcomposition comprise: A. contacting the sample with a binding moleculethat specifically binds a Lin⁺ marker under conditions to provide apopulation of Lin⁺ cells and a population of Lin⁻ cells, and recoveringthe population of Lin⁻ cells; B. contacting the Lin⁻ cells with abinding molecule that specifically binds CD34 and a binding moleculethat specifically binds CD25 under conditions to provide a population ofCD34⁺ cells, a population of CD25⁺ cells, and a population of CD34⁻CD25⁻ cells, and recovering the CD34⁺ cells and CD25⁺ cells andrecovering the population of CD34⁻ CD25⁻ cells; and C. contacting thepopulation of CD34⁻ CD25⁻ cells with a binding molecule thatspecifically binds CD45RA under conditions to provide a population ofCD45RA⁺ cells and a population of CD45RA⁻ cells, and recovering apopulation of CD45RA⁻ (see FIG. 4).

In some embodiments, step B further comprises contacting the Lin⁻ cellswith a CD1d-tet, a 6B11 monoclonal antibody or functional fragmentthereof, or a combination thereof under conditions to provide apopulation of CD1d-tet⁺ cells, 6B11⁺ cells, or a combination thereof,and recovering the CD1d-tet⁺ cells, 6B11⁺ cells, or a combinationthereof (see FIG. 4). In some embodiments, the method further comprisesperforming a fine sort of the CD34⁺ cells, CD25⁺ cells, CD1d-tet⁺ cells,6B11⁺ cells, or any combination thereof, thereby providing a populationCD34⁺ cells, CD25⁺ cells, CD1d-tet⁺ cells, 6B11⁺ cells, or anycombination thereof (see FIG. 4). In some embodiments, the fine sortcomprises contacting the CD34⁺ cells, CD25⁺ cells, CD1d-tet⁺ cells,6B11⁺ cells, or any combination thereof with a binding molecule thatspecifically binds CD34, a binding molecule that specifically binds CD4,a binding molecule that specifically binds CD25, a binding molecule thatspecifically binds CD127, a CD1d-tet, a 6B11 monoclonal antibody orfunctional fragment thereof, or any combination thereof under conditionsto provide a population of cells highly enriched for CD34⁺ cells, CD4⁺CD25⁺ CD127^(−/Lo) cells, CD1d-tet⁺ cells, or a combination thereof (seeFIG. 4).

Example Sort Scheme 4

In certain embodiments, the methods for producing a pharmaceuticalcomposition comprise: A. performing a rough sort of the sample toprovide a population of Lin⁺ cells and a population of Lin⁻ cells, andrecovering the population of Lin⁻ cells; B. performing a rough sort ofthe population of Lin⁻ cells provide a population of enriched in HSPCand Tmem and a population of CD45RA⁺ cells, and recovering thepopulation of HSPC and Tmem and recovering the population of CD45RA⁺cells; and C. performing a fine sort of the population of CD45RA⁺ cellsto provide a population of Treg (see FIG. 5). In some embodiments, thefine sort further comprises contacting the population of CD45RA⁺ cellswith a binding molecule that specifically binds CD34, a binding moleculethat specifically binds CD4, and a binding molecule that specificallybinds CD127 under conditions to provide a population of CD34+ cells anda population of CD4⁺ CD25⁺ CD127^(−/Lo) cells, and recovering apopulation of CD34+ cells and a population of CD4⁺ CD25⁺ CD127^(−/Lo)′cells. In some embodiments, the fine sort further comprises contactingthe population CD45RA⁺ cells with a CD1d-tet, 6B11 monoclonal antibodyor functional fragment thereof, or a combination thereof, and recoveringa population of CD1d-tet⁺ cells, 6B11⁺ cells, or a combination thereof.In some embodiments, the rough sort comprises density separation,tetrameric antibody complex mediated enrichment/depletion, magneticactivated cell sorting, apheresis, leukapheresis, or any combinationthereof.

Example Sort Scheme 5

In certain embodiments, the methods for producing a pharmaceuticalcomposition comprise: A. contacting the sample with a binding moleculethat specifically binds CD34 under conditions to provide a population ofCD34⁺ cells and a population of CD34⁻ cells, recovering the populationof CD34⁺ cells, and recovering the population of CD34⁻ cells; B.contacting the population of CD34⁻ cells with a binding molecule thatspecifically binds CD25 under conditions to provide a population ofCD25⁺ cells and a population of CD25⁻ cells, recovering the populationof CD25⁺ cells, and recovering the population of CD25⁻ cells; and C.contacting the population of CD25⁻ cells with a binding molecule thatspecifically binds CD45RA under conditions to provide a population ofCD45RA⁺ cells and a population of CD45RA⁻ cells, and recovering apopulation of CD45RA⁻ cells (see FIGS. 6, 10, 11, 12).

In some embodiments, step B further comprises: i. contacting thepopulation of CD34⁻ cells with a CD1d-tet, a 6B11 monoclonal antibody orfunctional fragment thereof, or a combination thereof under conditionsto provide a population of CD1d-tet⁺ cells, a population of 6B11⁺ cells,or a combination thereof and a population of CD1d-tet⁻ cells, apopulation of 6B11⁻ cells, or a combination thereof, and recovering apopulation of CD1d-tet⁺ cells, a population of 6B11⁺ cells, or acombination thereof, thereby providing a population of iNKT-depletedcells and recovering a population of CD1d-tet⁻ cells, a population of6B11⁻ cells, or both, thereby providing a population of iNKT-depletedcells; and ii. contacting the population of iNKT-depleted cells with abinding molecule that specifically binds CD25 under conditions toprovide a population of CD25⁺ cells and a population of CD25⁻ cells, andrecovering the population of CD25⁺ cells and recovering a population ofCD25⁻ cells (see FIG. 6).

In some embodiments, step B comprises contacting the population of CD34⁻cells with a binding molecule that specifically binds CD25, and aCD1d-tet, a 6B11 monoclonal antibody or functional fragment thereof, ora combination thereof under conditions to provide a population of CD25⁺cells and a population of CD1d-tet⁺ cells, 6B11⁺ cells, or a combinationthereof and a population of CD34⁻ CD25⁻ iNKT-depleted cells, andrecovering the population of CD25⁺ cells and the population of CD1d-tet⁺cells, 6B11⁺ cells, or a combination thereof, and recovering thepopulation of CD34⁻ CD25⁻ iNKT-depleted cells (see FIG. 10).

In some embodiments, step B comprises: i. contacting the population ofCD34⁻ cells with a binding molecule that specifically binds CD25, and aCD1d-tet, a 6B11 monoclonal antibody or functional fragment thereof, ora combination thereof under conditions to provide a population of CD25⁺cells and a population of CD1d-tet⁺ cells, 6B11⁺ cells, or a combinationthereof and a population of CD34⁻ CD25⁻ iNKT-depleted cells, andrecovering the population of CD25⁺ cells and the population of CD1d-tet⁺cells, 6B11⁺ cells, or a combination thereof, and recovering thepopulation of CD34⁻ CD25″ iNKT-depleted cells; and ii. performing a finesort of the population of CD25⁺ cells and the population of CD1d-tet⁺cells, 6B11⁺ cells, or a combination thereof by contacting the cellswith a binding molecule that specifically binds CD4, a binding moleculethat specifically binds CD25, a binding molecule that specifically bindsCD127, a CD1d-tet, a 6B11 monoclonal antibody or functional fragmentthereof, or any combination thereof, to provide a population of cellsenriched for CD4⁺ CD25⁺ CD127^(−/Lo) cells, CD1d-tet⁺ cells, 6B11⁺cells, or any combination thereof (see FIG. 11).

In some embodiments, step B comprises: i. contacting the population ofCD34⁻ cells with an anti-CD25 antibody that comprises a tag (e.g. afluorescent phycoerythrin), and a biotinylated 6B11 monoclonal antibody(6B11-biotin). The 6B11-biotin is then contacted with streptavidin thatis conjugated with the same tag as the anti-CD25 antibody. In someembodiments, the streptavidin is conjugated to phycoerythrin/Cy7(SAv-PE/Cy7). The cells are then contacted with anti-tag magneticparticles. In some embodiments, the magnetic particles are anti-PEmagnetic particles (e.g., magnetic beads). CD25⁺ cells and 6B11 boundcells are then separated using MACS to produce a population of CD25⁺cells and 6B11⁺ cells, and a population of CD34⁻ CD25⁻ iNKT-depletedcells (see FIG. 15). In some embodiments, Step B further comprises: ii.performing a fine sort of the population of CD25⁺ cells and 6B11⁺ cellsby contacting the cells with a binding molecule that specifically bindsCD4 and a binding molecule that specifically binds CD127 underconditions to provide a population of cells enriched forCD4⁺CD25⁺CD127^(−/Lo) cells and a population of cells enriched for 6B11⁺CD127⁺ cells, or any combination thereof. In some embodiments, the CD4binding molecule is anti-CD4 PerCP labeled antibody. In someembodiments, the CD127 binding molecule is anti-CD127 APC labeledantibody. The fine sort can comprise FACS wherein the CD25-PE,6B11-biotin-SAv-PE/Cy7, CD4-PerCP, and CD127-APC are detected.

In some embodiments, the population of CD34⁺ cells recovered in step A,the population of CD25⁺ cells recovered in step B, or both are furtherprocessed by a fine sort comprising contacting the CD34⁺ cells, theCD25⁺ cells, or a combination thereof with a binding molecule thatspecifically binds CD34, a binding molecule that specifically bindsCD127, a binding molecule that specifically binds CD45RA, or anycombination thereof (see FIG. 12)

Example Sort Scheme 6

In certain embodiments, the methods for producing a pharmaceuticalcomposition comprise: A. contacting the sample with a binding moleculethat specifically binds CD34 and a binding molecule that specificallybinds CD25 under conditions to provide a population of CD34⁺ cells, apopulation of CD25⁺ cells and a population of CD34⁻ CD25⁻ cells,recovering the population CD34⁺ cells and the population of CD25⁺ cells,and recovering the population of CD34⁻ CD25⁻ cells; and B. contactingthe population of CD34⁻ CD25⁻ cells with a binding molecule thatspecifically binds CD45RA under conditions to provide a population ofCD45RA⁺ cells and a population of CD45RA⁻ cells, and recovering thepopulation of CD45RA⁻ cells (see FIG. 7). In some embodiments, step Afurther comprises contacting the sample with a CD1d-tet, a 6B11monoclonal antibody or functional fragment thereof, or a combinationthereof under conditions to provide a population of CD1d-tet⁺ cells, apopulation of 6B11⁺ cells, or a combination thereof, and recovering thepopulation of CD1d-tet⁺ cells, the population of 6B11⁺ cells, or acombination thereof (see FIG. 7). In some embodiments, the methodfurther comprises performing a fine sort of the population of cellsprovided in step A by contacting the cells with a binding molecule thatspecifically binds CD34, a binding molecule that specifically binds CD4,a binding molecule that specifically binds CD25, a binding molecule thatspecifically binds CD127, a CD1d-tet, or any combination thereof, toprovide a population of cells enriched for CD34⁺ cells, CD4⁺CD25⁺CD127^(−/Lo) cells, CD1d-tet⁺ cells, or any combination thereof (seeFIG. 8).

Example Sort Scheme 7

In certain embodiments, the methods for producing a pharmaceuticalcomposition comprise simultaneously processing the sample to provide anenriched population of cells comprising HSPC, Tmem, naïve Treg, memoryTreg, and comprising less than 5% of undesired cells types (see FIG.13). In some embodiments, the sample is contacted with a bindingmolecule that specifically binds CD34, a binding molecule thatspecifically binds CD4, a binding molecule that specifically binds CD8,a binding molecule that specifically binds CD25, a binding molecule thatspecifically binds CD127, a binding molecule that specifically bindsCD45RA, a binding molecule that specifically binds CD45RO, or anycombination thereof. In some embodiments, the method further comprisescontacting the sample with a CD1d-tet, a 6B11 monoclonal antibody orfunctional fragment thereof, or a combination thereof, and recovering apopulation of CD1d-tet⁺ cells, a population of 6B11⁺ cells, or acombination thereof. In some embodiments, the sample is contacted with abinding molecule that specifically binds CD34 and recovering apopulation of CD34⁺ cells, thereby producing a population of HSPC. Insome embodiments, the sample is contacted with a binding molecule thatspecifically binds CD3 and do not bind a binding molecule thatspecifically binds CD45RA, a binding molecule that specifically bindsCD45RO, or a combination thereof, and recovering a population of CD3⁺CD45RA⁻ CD45RO⁺ cells. In some embodiments, the sample is contacted witha binding molecule that specifically binds CD4, a binding molecule thatspecifically binds CD25, a binding molecule that specifically bindsCD127, a binding molecule that specifically binds CD45RA, a bindingmolecule that specifically binds CD45RO, or any combination thereof, andrecovering a population of CD4⁺ CD25⁺ CD127^(−/lo)CD45RA⁺ CD45RO⁻ cells,a population of CD4⁺ CD25⁺ CD127^(−−/lo) CD45RA⁻ CD45RO⁺ cells.

In any of the aforementioned embodiments, the therapeutic cellpopulation comprises less than 2%, less than 1%, less than 0.5%, lessthan 0.1%, less than 0.01%, less than 0.001% naïve conventional αβ-Tcells.

In any of the aforementioned embodiments, the Lin⁺ marker can be CD19,CD11c, CD66B, CD14, CD20, or any combination thereof.

In any of the aforementioned embodiments, the molecule that specificallybinds a CD34, Lin+ marker, CD25, CD45RA, CDR45RO, CD4, CD8, CD127, CD90,CD133, CD38, CD95, CD122, CXCR3, LFA-1, CD62L, CCR7, or any othercellular marker is an antibody or an antibody fragment.

The term “antibody,” as used herein, is a broad term and is used in itsordinary sense, including, without limitation, to refer to naturallyoccurring antibodies as well as non-naturally occurring antibodies,including, for example, single chain antibodies, chimeric, bifunctionaland humanized antibodies, as well as antigen-binding fragments thereof.It will be appreciated that the choice of epitope or region of themolecule to which the antibody is raised will determine its specificity,e.g., for various forms of the molecule, if present, or for total (e.g.,all, or substantially all, of the molecule).

Methods for producing antibodies are well-established. One skilled inthe art will recognize that many procedures are available for theproduction of antibodies, for example, as described in Antibodies, ALaboratory Manual, Ed Harlow and David Lane, Cold Spring HarborLaboratory (1988), Cold Spring Harbor, N.Y. One skilled in the art willalso appreciate that binding fragments or Fab fragments that mimicantibodies can be prepared from genetic information by variousprocedures (Antibody Engineering: A Practical Approach (Borrebaeck, C.,ed.), 1995, Oxford University Press, Oxford; J. Immunol. 149, 3914-3920(1992)). Monoclonal and polyclonal antibodies to molecules, e.g.,proteins, and markers also commercially available (R and D Systems,Minneapolis, Minn.; HyTest Ltd., Turk, Finland; Abcam Inc., Cambridge,Mass., USA, Life Diagnostics, Inc., West Chester, Pa., USA; FitzgeraldIndustries International, Inc., Concord, Mass., USA; BiosPacific,Emeryville, Calif.).

In some embodiments, the antibody is a polyclonal antibody. In otherembodiments, the antibody is a monoclonal antibody. In embodiments, theantibodies of the disclosure are compatible with downstream applicationsof the cell populations extracted according to the present methods. Forexample, the antibodies of the disclosure can be non-immunogenic,humanized antibodies. In some embodiments, the antibodies of thedisclosure comprise an epitope tag useful to immobilize the antibodybefore or after extraction of the sample, thereby depleting the antibodyfrom the extracted cell population.

In some embodiments, the antibody is a biotinylated 6B11 antibody. 6B11is an antibody that binds to the invariant TCR Va24Ja18. In someembodiments, the 6B11 antibody is biotinylated at pH 5.5-6.0, 6.0-6.5,6.5-7, 7.5-8, 8-8.5, 8.5-9, 9-9.5, or 9.5-10. In some embodiments, the6B11 antibody is biotinylated in with buffering agents phosphate,borate, or hepes. In some embodiments, the buffer is an amine freebuffer. The biotinylation reaction may be performed at about 0 mM NaCl,50 mM NaCl, 100 mM NaCL, 150 mM NaCl, 300 mM NaCl, or 500 mM NaCl orintermediate values. Modification sites of the protein (e.g., antibody)include free amines, free thiols, and carbohydrates, artificiallyintroduced azides, and artificially introduced alkynes. Concentrationsof biotin may be varied from 10 μM-50 μM, 50 μM-100 μM, 100 μM-250 μM,250 μM-500 μM, 500 μM-1 mM, 1 mM-2 mM, 2 mM-5 mM, 5 mM-10 mM. Reactiontimes may vary from 10-30 minutes, 30 minutes-1 hour, 1 hour 1.5 hours,1.5 hours-2.5 hours, 2.5 hours-6 hours, 6 hours-10 hours, 10 hours-18hours. The biotinylated 6B11 antibody disclosed herein may be used inany of the methods disclosed herein to sort, purify, or isolatepopulations of Va24Ja18⁺ cells (iNKT cells).

Capture binding partners and detection binding partner pairs, e.g.,capture and detection antibody pairs, can be used in embodiments of thedisclosure. Thus, in some embodiments, a sorting and purificationprotocol is used in which, typically, two binding partners, e.g., twoantibodies, are used. One binding partner is a capture partner, usuallyimmobilized on a particle, and the other binding partner is a detectionbinding partner, typically with a detectable label attached. Suchantibody pairs are available from several commercial sources, such asBiosPacific, Emeryville, Calif. Antibody pairs can also be designed andprepared by methods well-known in the art. In a particular embodiment,the antibody is biotinylated or biotin labeled.

In some embodiments, there is a second imaging component that binds allmembers of the starting cell population non-specifically. Therefore,this signal can be read to normalize the quantity of fluorescencebetween cavities. One example is an antibody that will bind a protein orproteins that are ubiquitously expressed on the cell surface of astarting population of cells.

In some embodiments, the antibody or antibody fragment is coupled to orlabeled with a fluorescent dye, a hapten, or a magnetic particle.

Several strategies that can be used for labeling binding partners toenable their detection or discrimination in a mixture of particles arewell known in the art. The labels can be attached by any known means,including methods that utilize non-specific or specific interactions. Inaddition, labeling can be accomplished directly or through bindingpartners.

Emission, e.g., fluorescence, from the moiety should be sufficient toallow detection using the detectors as described herein. Generally, thecompositions and methods of the disclosure utilize highly fluorescentmoieties, e.g., a moiety capable of emitting electromagnetic radiationwhen stimulated by an electromagnetic radiation source at the excitationwavelength of the moiety. Several moieties are suitable for thecompositions and methods of the disclosure.

Labels activatable by energy other than electromagnetic radiation arealso useful in the disclosure. Such labels can be activated by, forexample, electricity, heat or chemical reaction (e.g., chemiluminescentlabels). Also, a number of enzymatically activated labels are well knownto those in the art.

Typically, the fluorescence of the moiety involves a combination ofquantum efficiency and lack of photobleaching sufficient that the moietyis detectable above background levels in the disclosed detectors, withthe consistency necessary for the desired limit of detection, accuracy,and precision of the assay.

Furthermore, the moiety has properties that are consistent with its usein the assay of choice. In some embodiments, the assay is animmunoassay, where the fluorescent moiety is attached to an antibody;the moiety must have properties such that it does not aggregate withother antibodies or proteins, or experiences no more aggregation than isconsistent with the required accuracy and precision of the assay. Insome embodiments, fluorescent moieties dye molecules that have acombination of 1) high absorption coefficient; 2) high quantum yield; 3)high photostability (low photobleaching); and 4) compatibility withlabeling the molecule of interest (e.g., protein) so that it can beanalyzed using the analyzers and systems of the disclosure (e.g., doesnot cause precipitation of the protein of interest, or precipitation ofa protein to which the moiety has been attached).

A fluorescent moiety can comprise a single entity (a Quantum Dot orfluorescent molecule) or a plurality of entities (e.g., a plurality offluorescent molecules). It will be appreciated that when “moiety,” asthat term is used herein, refers to a group of fluorescent entities,e.g., a plurality of fluorescent dye molecules, each individual entitycan be attached to the binding partner separately or the entities can beattached together, as long as the entities as a group provide sufficientfluorescence to be detected.

In some embodiments, the fluorescent dye molecules comprise at least onesubstituted indolium ring system in which the substituent on the3-carbon of the indolium ring contains a chemically reactive group or aconjugated substance. Examples include Alexa Fluor molecules.

In some embodiments, the labels comprise a first type and a second typeof label, such as two different ALEXA FLUOR® dyes (Invitrogen), wherethe first type and second type of dye molecules have different emissionspectra.

A non-inclusive list of useful fluorescent entities for use in thefluorescent moieties includes: ALEXA FLUOR® 488, ALEXA FLUOR® 532, ALEXAFLUOR® 555, ALEXA FLUOR® 647, ALEXA FLUOR® 700, ALEXA FLUOR® 750,Fluorescein, B-phycoerythrin, allophycocyanin, PBXL-3, Atto 590 and Qdot605.

Labels can be attached to the particles or binding partners by anymethod known in the art, including absorption, covalent binding,biotin/streptavidin or other binding pairs. In addition, the label canbe attached through a linker. In some embodiments, the label is cleavedby the analyte, thereby releasing the label from the particle.Alternatively, the analyte can prevent cleavage of the linker.

The separated cell populations can be used immediately or can becultivated in vitro after isolation using methods well known in the art.The cell populations can be cultured in media, such as RPMI-1640, DMEM,X-Vivo 10, X-vivo 15, or variants and combinations thereof. The mediacan comprise from 1-20% human serum. The media can comprise cytokines ormolecules that activate the receptors for, such as, rapamycin, SCF,SDF-1, TPO, IL-2, IL-3, IL-4, IL-6, IL-7, IL-10, IL-15, IL-17, IL-18,IL-23, IL-33, TGF-b, IFNg, IFNa with combinations thereof. The cellpopulations can be stimulated with agonists such as particles(microparticles, nanoparticle, proteins, or cells) that containmultivalent display of binding molecules such as anti-CD3, anti-CD28,CD64, CD86, anti-IL-21R, CD137, or combinations thereof.

In addition, the cells can be frozen or they can be frozen before orafter being separated. In case the cells are to be stored for a longerperiod of time it is preferred to do so at around −80° C. or in liquidnitrogen in order to in ensure that the cells can be used again afterthawing. For this purpose, the cells are normally stored in DMSO and/orFCS/HS together with a medium, glucose etc. Immediately after the cellshave been thawed, the cells can either be used directly for therapeuticpurposes or in vitro experiments or they can be expanded and/ordifferentiated using growth factors, antigens, cells etc.

Example 1 Production of Sculpted Cellular Graft

The enrichment and depletion of cells occurs in multiple steps towardformulation of the final product for infusion. Each selection procedureis described in the following with a brief description of the procedure.This process is outlined in FIG. 14.

Step A:

CD34⁺ cell enrichment was performed using immunomagnetic cell selectionon the CLINIMACS Cell Selection System (Miltenyi Biotec,Bergish-Gladbach, Germany). Briefly, donor apheresis products werepooled, when two apheresis products were collected and washed to removeexcess plasma and platelets. The volume was adjusted to that indicatedfor the cell number and CD34⁺ cell content under the manufacturer'sguidelines with CLINIMACS Buffer supplemented with 0.5% HSA (workingbuffer) and IVIg added to reduce non-specific binding of the Miltenyimicrobead reagents to cells. The cellular product was labeled withCLINIMACS CD34 reagent using the manufacturer's guidelines for productcontent. Unbound reagent was reduced by dilution with working buffer andremoval by centrifugation. The labeled cell product was connected to theCLINIMACS device, which controls the loading of the cells into thesingle use tubing set for immunomagnetic selection of the labeled cells.Retained cells were released by removal of the magnetic field anddirected to the Positive Fraction bag attached to the CLINIMACS tubingset. The CD34⁺ enriched cells were re-suspended in Normosol-Rsupplemented with 2% HSA as the designated infusion medium. The Negativefraction (CD34 selection flow-through) was retained for further cellprocessing.

Step B:

Regulatory T cells and iNKT cells were enriched from the Step A Negativefraction (CD34 selection flow-through) by immunomagnetic selection usingthe CLINIMACS system. The fraction volume was adjusted and the cellslabeled with PE/Cy7-conjugated CD1d (glycolipid loaded) tetramer reagentand Miltenyi Biotec's anti-CD25 PE reagent. After washing to removeunbound reagent from the cell suspension, the cells were labeled withanti-PE microbead reagent, washed to remove unbound beads, and loadedonto the CLINIMACS using the LS tubing set. The labeled cells wereretained on the magnetized column. Upon removal of the magnetic field,the CD25⁺ and CD1d (glycolipid loaded) tetramer⁺ cells were releasedfrom the column to the Positive fraction bag attached to the tubing set.The flow-through (Negative fraction) containing cells depleted of CD25⁺and CD1d (glycolipid loaded) tetramer⁺ cells were retained for asubsequent cell selection procedure (Step C, below). The enrichment ofCD25⁺ cells and CD1d (glycolipid loaded) tetramer⁺ cells was anintermediate step for further enrichment in Step D, below.

Step C:

Cells in the CD25/CD1d enrichment Negative fraction were separated intonaïve and memory subsets by immunomagnetic selection using CD45RAexpression as an indicator of donor memory cells. Cells were preparedand labeled with CLINIMACS CD45RA reagent. After washing to removeunbound reagent from the cell suspension, the cells were loaded instages onto the CLINIMACS equipped with a depletion tubing set. Thelabeled cells were retained on the magnetized column and removed fromthe column to the Target Cell bag attached to the tubing set. Theflow-through fraction contains cells depleted of CD45RA⁺ cells wereadded to the final product to ensure inclusion of donor memory cells.

Step D:

Treg and iNKT cells were further purified by cell sorting using a BDFACS ARIA. The CD25⁺ cells recovered by enrichment of CD25⁺ and CD1d(glycolipid loaded) tetramer⁺ cells in Step B were volume adjusted forlabeling with PerCP-conjugated mouse anti-human CD4 and APC-conjugatedmouse anti-human CD127 monoclonal antibody reagents and additional CD25PE (Miltenyi Biotec) and CD1d (glycolipid loaded) tetramer PE-Cy7. Afterwashing to remove unbound reagent, the cells were sorted with gates setfor single, lymphocyte cells containing the molecular phenotype ofCD4-PerCP⁺×CD25 PE+, CD127-APC dim/neg cells (Treg) and the CD127+×CD(glycolipid loaded) tetramer-PE/Cy7⁺ (iNKT).

Cell subsets recovered from cell selection procedures and intended forinfusion were resuspended in Normosol-R, pH 7.2 (Hospira, Lake Forest,Ill.) supplemented with 0.5% HSA (Albumin-Human, 25%, Grifols, Clayton,N.C.). The cell fractions were combined in a single blood transfer bagat a maximum density of 1×10⁸ cell/ml and placed at 2 to 8° C. in acontinuously monitored, secure refrigerator.

Example 2 Production of Sculpted Cellular Graft with Anti-iNKT Antibody

The enrichment and depletion of cells occurs in multiple steps towardformulation of the final product for infusion. Each selection procedureis described in the following with a brief description of the procedure.This process is outlined in FIG. 15.

Step A:

CD34⁺ cell enrichment was performed using immunomagnetic cell selectionon the CLINIMACS Cell Selection System (Miltenyi Biotec,Bergish-Gladbach, Germany). Briefly, donor apheresis products werewashed to remove excess plasma and platelets. If two donor apheresisproducts were collected they were pooled. The volume was adjusted tothat indicated for the cell number CD34⁺ cell content under themanufacturer's guidelines with CLINIMACS Buffer supplemented with 0.5%HSA (working buffer) and IVIg added to reduce non-specific binding ofthe Miltenyi microbead reagents to cells. The cellular product waslabeled with CLINIMACS CD34 reagent using the manufacturer's guidelinesfor product content. Unbound reagent was reduced by dilution withworking buffer and removal by centrifugation. The labeled cell productwas connected to the CLINIMACS device, which controls the loading of thecells into the single use tubing set for immunomagnetic selection of thelabeled cells. Retained cells were released by removal of the magneticfield and directed to the Positive Fraction bag attached to theCLINIMACS tubing set. The CD34⁺ enriched cells were re-suspended inNormosol-R supplemented with 2% HSA as the designated infusion medium.The Negative fraction (CD34 selection flow-through) was retained forfurther cell processing.

Step B:

Regulatory T cells and iNKT cells were enriched from the Step A Negativefraction (CD34 selection flow-through) by immunomagnetic selection usingthe CLINIMACS system. The fraction volume was adjusted and the cellslabeled with anti-CD25-PE (Miltenyi Biotec) and biotin conjugated 6B11monoclonal antibodies (anti-iNKT). After washing to remove unboundreagent from the cell suspension, the cells were labeled withPE/Cy7-conjugated streptavidin and washed again. The cells were thenlabeled with anti-PE microbead reagent (Miltenyi Biotec), washed toremove unbound beads, and loaded onto the CLINIMACS using the LS TStubing set using the CD133 enrichment program. The labeled cells wereretained on the magnetized column. Upon removal of the magnetic field,the CD25⁺ and 6B11⁺ cells were released from the column to the targetfraction bag attached to the tubing set. The flow-through (non-targetfraction) containing cells depleted of CD25⁺ and 6B11⁺ cells wereretained for a subsequent cell selection procedure (Step D, below). Theenrichment of CD25⁺ cells and 6B11⁺ cells is an intermediate step forfurther enrichment in Step C, below.

Step C:

Treg and iNKT cells were further purified by fluorescence activated cellsorting. The CD25⁺ cells recovered by enrichment of CD25⁺ and 6B11⁺cells in Step B were volume adjusted for labeling with PerCP-conjugatedmouse anti-human CD4 (Miltenyi Biotec) and APC-conjugated mouseanti-human CD127 monoclonal antibody reagents (Miltenyi Biotec), andadditional CD25 PE (Miltenyi Biotec) and Streptavidin PE-Cy7. Afterwashing to remove unbound reagent, the cells were sorted with gates setsingle, lymphocyte cells containing the molecular phenotype ofCD4-PerCP⁺×CD25 PE+, CD127-APC dim/neg cells (Treg) and theCD127+×6B11-PE/Cy7⁺ (iNKT).

Step D:

Cells in the CD25/6B11 Negative fraction were separated into naïve andmemory subsets by immunomagnetic selection using CD45RA expression as anindicator of donor memory cells. Cells were prepared and labeled withCLINIMACS CD45RA reagent. After washing to remove unbound reagent fromthe cell suspension, the cells were loaded in stages onto the CLINIMACSequipped with a depletion tubing set. The labeled cells were retained onthe magnetized column and removed from the column to the Target Cell bagattached to the tubing set. The flow-through fraction contains cellsdepleted of CD45RA⁺ cells were added to the final product to ensureinclusion of donor memory cells.

Cell subsets recovered from cell selection procedures and intended forinfusion were resuspended in Normosol-R, pH 7.2 (Hospira, Lake Forest,Ill.) supplemented with 0.5% HSA (Albumin-Human, 25%, Grifols, Clayton,N.C.). The cell fractions were combined in a single blood transfer bagat a maximum density of 1×10⁸ cell/ml and placed at 2 to 8° C. in acontinuously monitored, secure refrigerator.

TABLE 1 Reagents and target cells numbers for an exemplary sculptedgraft composition. Sculpted Molecular Phenotype Dosage: Graft forSculpted Graft Exemplary Isolation Number of Component IsolationReagents Cells/kg HSPC CD34⁺ Anti-CD34+ microbeads 1 × 10⁶-1 × 10⁷(Miltenyi) Treg CD34⁻ Anti-CD4 PerCP 0.5 × 10⁶-5 × 10⁶   CD4⁺ Anti-CD25PE (Miltenyi) CD25⁺ Anti-CD127 APC (Miltenyi) CD127^(dim/−) Anti-PEmicrobeads iNKT CD34⁻ 6B11-biotin   1 × 10⁴-2.5 × 10⁶ TCR Vα24Jα18⁺Streptavidin PE-Cy7 CD127⁺ Anti-CD127 APC (Miltenyi) Anti-PE microbeadsTmem CD34⁻ Anti-CD45RA 1 × 10⁶-1 × 10⁸ CD25⁻ CD45RA⁻ Tnaive CD34⁻Anti-CD45RA <75,000 (contaminant) CD25⁻ CD45RA⁺

Example 3 Sculpted Cellular Graft Versus T Cell Replete & T CellDepleted Allografts in a Murine Model of Myeloablative HematopoieticCell Transplant (Alloma-HCT)

A murine model of myeloablation and cellular graft transplant was usedto assess the performance of an exemplary sculpted cellular graftdescribed herein compared to known cellular grafts. FIG. 16 depicts adiagram of the experimental procedure. To model myeloablated patients,8-12 week old BALB/c recipient mice were weighed and then irradiatedwith a split dose of 400/400 rad from a Rad-Source RS2000 irradiator at160 KeV filtered through 0.5 mm Cu on day −2. Mice were switched toantibiotic food for 6 weeks. To model residual disease, 2,500-10,000J774 GFP-Luc cells were injected intravenously into each mouse via thetail vein on day −1. The J774 cell line is a myeloid cell lineoriginally derived from BALB/c mice and are syngeneic to the BALB/crecipient mice. The J774 cells were modified to express a GFP andLuciferase transgene. The three different cellular compositionssummarized in Table 2 were used to model allogeneic hematopoietic celltransplantation (HCT). The cellular compositions were prepared asdescribed below from the hematopoietic tissue of C57Bl/6 mice andinfused intravenously through the retro-orbital plexus of the BALB/cmice on day 0. Experimental cohorts were generally 5-9 mice. Data fromseven independent experiments were pooled and represented in the FIG.17.

TABLE 2 Cellular compositions administered to BALB/c mice. CellularComposition Cell Types Bone Marrow Transplant HSPC: 1 × 10⁶-2 × 10⁶cKIT⁺ magnetically (BMT) enriched bone marrow cells Tcon: 1 × 10⁵-1 ×10⁷ splenocytes Hematopoietic Stem Cell HSPC: 1 × 10⁶-2 × 10⁶ cKIT⁺magnetically Transplant (HSPT) enriched bone marrow cells SculptedCellular Graft HSPC: 1 × 10⁶-2 × 10⁶ cKIT⁺ magnetically enriched bonemarrow cells Treg: 5 × 10³-5 × 10⁴ FACS sorted CD4⁺CD25^(bright)splenocytes iNKT: 1 × 10⁴-1 × 10⁶ FACS sortedCD1d-tetramer_(PBS-57 loaded)+ splenocytes CD8 Tmem: 2.5 × 10⁴-1.25 ×10⁵ FACS sorted CD8⁺CD44⁺CD62L^(mid/low) splenocytes CD4 Tmem: 7.5 ×10⁴-3.75 × 10⁵ FACS sorted CD4⁺CD44⁺CD62L^(mid/low) splenocytes

Mice were checked daily for distress. Body condition (BC) score and bodyweights were measured twice weekly. Mice with BC≤1.5 were euthanized.Mice that died with body weights <70% of their original weight werescored as GVHD. Mice that died within 30 days post-transplant >70% bodyweight were scored engraftment failure. All dead mice were dissected andinspected for tumor growth in liver and spleen with a fluorescentmicroscope. The presence of GFP+ tumor nodules was scored as relapse(see FIG. 17C). Some cohorts of mice were subjected to bioluminescentimaging on a Xenogen IVIS100 on day+10 (see FIG. 17D).

Mice receiving the sculpted cellular graft composition outperformed allother cohorts (see FIGS. 17A and B). 94% of these mice survived today+175 with no evidence of relapse. 3% of these mice died from GVHD and3% died from engraftment failure. The improved performance compared toBMT and HSPC compositions indicates that the GvL effect has beenmaintained, but the GVHD and engraftment failure rates are significantlyreduced.

In comparison, all mice receiving a BMT composition of cells succumbedto GVHD before day +30. No evidence of relapse was found in these micein bioluminescent imaging at day +10. Furthermore, no tumor nodulegrowth on the hematopoietic organs was observed in post mortem analysis.This result indicates the T cells in the graft were sufficient tocounteract the cancer cells, and indicates strong GvL from the graftalbeit in the background of uniformly lethal GVHD. It is noted that inhuman patients, allograft sources are closely matched to the recipientby HLA-haplotype, whereas BALB/c and C57Bl/6 mice are fully mismatched.Therefore, the GVHD reaction observed in the clinic is stronglymitigated relative to the GVHD reaction observed here.

Mice receiving a HSCT composition of cells had mixed outcomes. 51% ofmice survived long term to day +175. 9% of HSCT recipients died fromengraftment failure as evidenced by death before day +30 at a bodyweight >70%. 3% of mice died from GVHD, as evidenced as body weight <70%at the last measurement before the time of death. 36% of mice hadevidence of relapse at the time of death. The high rate of relapse inthis cohorts results from prolonged immunosuppression after HSCT, as Tcell counts remain low in the early weeks after transplant. Incomparison, human HSCT recipients also suffer low T cell counts for thefirst year after transplant and higher rates of relapse. Therefore, theHSCT transplant model mirrors the lack of GvL in human patients due to Tcell depletion. An increased relapse rate is observed in human patientstreated with CD34⁺ allografts relative to T cell-replete allografts.

Example 4 Comparison of Sculpted Cellular Grafts Produced by Macs/FacsVs Mac S-Only a Murine Model of Alloma-HCT

This experiment compares the sculpted cellular graft composition datashown above with another cohort of mice. GVL and GVHD were assessed inanimals treated with a sculpted cellular graft produced by MACS-only ora sculpted cellular graft produced by combination of MACS and FACS (seeTable 3). These mice were prepared and followed as above. Cohorts were5-7 mice and the data is pooled from 3 independent experiments.

TABLE 3 Sculpted cellular graft produced by MACS- only or a combinationof MACS and FACS Cellular Composition Cell Types MACS-only SculptedHSPC: 1 × 10⁶-2 × 10⁶ cKIT⁺ magnetically Cellular Graft enriched bonemarrow cells Treg: 5 × 10³-5 × 10⁴ magnetically enriched CD25⁺splenocytes iNKT: 1 × 10⁴-1 × 10⁶ magnetically enrichedCD1d-tetramer_(PBS-57 loaded)+ splenocytes Tmem: 2.5 × 10⁴-1.25 × 10⁵magnetically enriched CD44⁺ splenocytes MACS/FACS Sculpted HSPC: 1 ×10⁶-2 × 10⁶ cKIT⁺ magnetically Cellular Graft enriched bone marrow cellsTreg: 5 × 10³-5 × 10⁴ FACS sorted CD4⁺CD25^(bright) splenocytes iNKT: 1× 10⁴-1 × 10⁶ FACS sorted CD1d-tetramer_(PBS-57 loaded)+ splenocytes CD8Tmem: 2.5 × 10⁴-1.25 × 10⁵ FACS sorted CD8⁺CD44⁺CD62L^(mid/low)splenocytes CD4 Tmem: 7.5 × 10⁴-3.75 × 10⁵ FACS sortedCD4⁺CD44⁺CD62L^(mid/low) splenocytes

The MACS/FACS sculpted cellular graft mice were prepared using acombination of MACS and FACS as described in Example 3. FACS puritiesare typically greater than 95%. In comparison, the purity of MACS-onlyenriched samples is typically 20%-80%. The allogeneic lymphocytes of theMACS-only mice were not further purified by FACS, and the therapeuticbenefit of this composition was severely impaired. Only 54% of MACS-onlymice were alive by day+175 compared to 94% survival of MACS/FACSsculpted cellular graft mice (see FIG. 18). All fatal cases exhibitedbody weights <70% of the starting weight, indicating GVHD as the causeof death. None of these mice showed post-mortem evidence of relapse. Thehigh levels of lethal GVHD in the MACS-only manufacturing compared tothe MACS/FACS method of manufacturing demonstrate the importance ofpurity for these cell populations in the context of graft-engineering ofa myeloablative hematopoietic cell transplant (MA-HCT). While notwishing to be bound by theory, the prevalence GVHD in mice treated withthe MACS only sculpted cellular graft is thought to be the result ofcontamination Tcon cells.

Example 5 Comparison of Sculpted Cellular Graft Vs BMT with T CellAdd-Back in a Murine Model of Alloma-HCT

A sculpted cellular graft composition was compared against cohorts thatwere administered BMT compositions with varying amounts of T cells addedto the cKIT+ HSPC fraction (HSPC+ T cell add-back). By way ofbackground, T cell add-back is an experimental clinical approach to bonemarrow transplant. As an example, clinical centers perform a T celldepletion (e.g., usually a CD34+ cell CLINIMACS isolation), and then addback some of the T cells to the graft or transplant them at a laterdate. Note that in the add-back procedure the T cells are bulk T cells,as T cells are provided from the collected CD34⁻ fraction and are notfurther processed. T cells are typically reintroduced at levels 10-1000times less than the naturally occurring level in a BMT graft.

In the instant example, each add-back cohort was administered a cKIT+HSPC fraction that contained 1×10⁵, 2×10⁵, 4×10⁵, or 2×10⁶ add-back Tcells from splenocytes. In comparison, the sculpted cellular graftcontained a mean of 2.5×10⁵ T cell. However, some sculpted cellulargraft experiments employed as many as 5×10⁶ sculpted T cells and othersas few as 1×10⁵ sculpted T cell.

In the context of fully mismatch C57Bl/6 lymphocytes adoptivelytransferred into BALB/c mice, even 1×10⁵ T cells was sufficient toinduce lethal GVHD in 100% of the recipients (FIG. 19). Note that thetime to death was prolonged in mice that were administered between 1×10⁵and 4×10⁵ add-back T cells, but no mouse survived long-term. Incontrast, 94% (30/32) of the sculpted cellular graft treated micedemonstrated long term survival to day+175. None of the mice displayedpost-mortem evidence of relapse. Therefore, the T cell component of thesculpted cellular graft composition both mitigates the GVHD response andimparts a GVL therapeutic benefit. A similar result is not observed by asimply adding back a reduced number of T cells to cKIT+ magneticallyenriched bone marrow cells.

Example 6 Delayed Time to Onset of GVHD with Human-Derived SculptedCellular Grafts Vs Unprocessed PBMCS in a Xenograft Model of Allo-HCT

White blood cell concentrate of TrimaAccel® LRS chamber were recoveredafter Plateletpheresis procedure from 4 human donors. Red blood cellswere removed by a density gradient (Ficoll) and ACK lysis. The resultingPBMCs were washed and 2.5×10⁸ cells from each donor were processedsculpted cellular graft lymphocyte fractions. More specifically, Tregsand iNKTs were initially processed using MACS (i.e., rough sorting). Thesamples were stained with anti-CD25 PE and the biotin conjugatedanti-iNKT antibody, 6B11, and then washed; stained with StreptavidinPE-Cy7 and then washed again; and stained with anti-PE microbeads. Thesample was then positively enriched using a Possel_S program on aMiltenyi AutoMACS. The positively enriched fraction was further stainedwith anti-CD127 APC and anti-CD4 PerCP and further purified on a BDFACSAriaII to >98% purity according to the parameters: Treg:CD4⁺CD25⁺CD127⁻ and iNKT: CD127⁺ 6B11⁺.

The negative fraction from the AutoMACS column was further stained withanti-CD45RA microbeads and the Deplete _S program was used to depletethe naïve T cells in the CD45RA+ fraction. The remaining cells wereCD45RA−CD45RO+, which is indicative of memory T cells.

Sculpted cellular grafts were formulated based on the final yield ofeach subtype which varied between donors. PBMC cohorts were formulatedto match an equal number of CD3⁺ T cells with the number of memory Tcells in the sculpted cellular graft composition from the matched donor.The final formulations ranges are represented in Table 4.

TABLE 4 Lymphocyte formulations Sculpted Cellular GraftLymphocytes/Mouse PBMC/mouse 7.5 × 10⁴-1.5 × 10⁵ Treg 2 × 10⁶-6 × 10⁶Total Nucleated Cell 5 × 10³-1.5 × 10⁴ iNKT Count (1 × 10⁶-3 × 10⁶ CD3⁺)1 × 10⁶-3 × 10⁶ Memory T cells

For the Xenograft experiments, immunodeficient (NSG) mice were usedbecause a functional murine immune system would quickly reject theincoming human tissue based on species-specific differences. NSG micelack B, T, and NK cells making it a suitable host for xenograftexperiments. To further prepare the host to engraft lymphocytes, themice are given a non-lethal dose of radiation. NSG were irradiated with250 rad from a Rad-Source RS2000 irradiator at 160 KeV filtered through0.5 mm Cu and switched to antibiotic feed. On the same day theformulated cells were injected into 5 mice per cohort for each donor andtracked as described above. In this context, human PBMCs are known toelicit a robust GVHD response. The results demonstrate that 70% of themice receiving the sculpted cellular graft lymphocytes survive today+90, compared to only 15% of mice receiving an equal dose of CD3+cells in the PBMCs (see FIG. 20). GVHD was scored as the cause of deathin all cases of death. The xenogeneic response of human lymphocytesagainst murine tissue is robust; however, the sculpted cellular graftdoes not only delay the onset of lethal GVHD (which would have clinicalvalue), but rather it results in durable survival for a significantfraction of the mice.

Example 7 Isolation of Regulatory T Cells and iNKTs

The following experiments demonstrate methods for producing Treg andiNKT cell fractions for use in a sculpted cellular graft composition andtherapy. Peripheral blood monocytes (PBMCs) were isolated from buffycoat LRS chambers as in Example 6 from 3 donors. The PBMCs were pooledand then resuspended and stained at a concentration of 2×10⁸ cells/ml.Tregs were stained with anti-CD25 PE and iNKT cells were stained thebiotin conjugated 6B11 antibody (anti-iNKT) for 30 minutes at roomtemperature, washed, and then stained with Straptavidin PE-Cy7 for 10minutes at room temperature. Excess antibody was removed by washing thecells with buffer before staining with anti-PE microbeads at 2×10⁸cells/mL. Cells were stained with the anti-PE microbeads for 30 minutesat room temperature. After staining, cells were washed with buffer andfiltered through a 40 micron pore mesh to remove clumps beforeseparation. A CLINIMACS LS TS tubing set was used to sort the cellsusing the manufacturer's CD133 enrichment protocol (loading speed: 10 mLper min, 3 re-loads). The Treg and iNKT enriched cells were collected inthe positive fraction and the remaining cells were collected in thenegative fraction. A fraction of known volume relative to the measuredvolume of the sample of each sample was removed and counted on a BeckmanCoulter Cytoflex using reference beads and used to calculate yields.

The performance of the separation of Tregs and iNKT cells from PBMCs wasassessed by calculating the purity and yield of Treg and iNKT cells inthe enriched fraction relative to the pre-enriched cells. In arepresentative experiment using anti-PE beads, the purity of Tregsincreased from about 5% to 60%, (FIG. 21A and Table 5). The anti-PEbeads tested increased the purity of the NKT cells from 0.02% to 0.04%(FIG. 21B and Table 6).

TABLE 5 Percent purity and yield of Treg cells. CliniMACS anti PE bead/Purity Yield Enrichment million cells (%) (%) Expt 1 0.1 μl 57.4 31.3Expt 2 0.2 μl 38.9 39.2 Expt 3 0.5 μl 32.3 37.4

TABLE 6 Percent purity and yield of iNKT cells Enrichment anti PE bead/Purity Program million cells (%) Expt 1 0.1 ul 0.04 Expt 2 0.2 ul 0.03Expt 3 0.5 ul 0.04

These data demonstrate that by carefully titrating the magneticselection reagent, higher purities of enriched cells can be obtainedwithout adversely compromising the yield. In addition, that the negativefraction can be re-processed with similar or identical conditions as thecrude PBMC product to recover more target cell. This unexpected findingenables a process that meets the target specifications for thepost-CLINIMACS Treg/iNKT fraction.

Example 8 Isolation of Memory T Cells

PBMCs were isolated from buffy coat LRS chambers as in Example 6 from 3donors. The PBMCs were pooled and then 1×10⁹ cells were resuspended at2×10⁸ cells/mL. The cells were stained with half of the manufacturer'srecommended usage of CD45RA microbeads (0.5 μL anti-CD45RA per 6.6×10⁶PBMCs rather than 1.0 μL anti-CD45RA per 6.6×10⁶ PBMCs). The cells werewashed and run on CLINIMACS Depletion 2.1 (6 mL/min flow rate). Bothpositive and negative fractions were harvested and analyzed. A fractionof known volume relative to the measured volume of the sample fractionof each sample was removed and stained with fluorescently conjugatedmonoclonal antibodies against CD3, CD45RA, and CD45RO, washed, andcounted on a Beckman Coulter CYTOFLEX flow cytometer using referencebeads to calculate purity and yields (FIG. 22).

The performance of the separation of naïve T cells (Tn) and memory Tcells was assessed by calculating the purity and yield of CD3⁺CD45RA⁺and CD3⁺ CD45RO⁺ cells in the enriched fraction relative to thepre-enriched cells. Using half the manufacturer recommended dosage ofCD45RA microbeads, the ratio of Tmem to Tn went from 2.25:1 in thestarting PBMC sample to 50298:1 in the processed sample (Table 7).Furthermore, the yield of Tmem after this process was 27.5%. Thesestudies demonstrate the feasibility of manufacture of a sculptedcellular graft with a reduced amount of CD45RA microbeads.

TABLE 7 Performance of memory T cell enrichment using magnetic sortingto depleted CD45RA⁺ cells CD45RA depletion Tmem:Tn Yield 1 μl reagentper 12.3M 50298 27.5% Target 10000 66.0% Min 10000 22.0%

Example 9 Isolation of Regulatory T Cells and Naïve Regulatory T Cells

The following experiment characterizes Treg populations produce anexemplary method disclosed herein. PBMCs were isolated from buffy coatLRS chambers as in Example 6 from 2 donors. The PBMCs were pooled andthen resuspended and stained at a concentration of 2×10⁸ cells/ml. Tregssorted using anti-CD25 magnetic microbeads. A CLINIMACS LS TS tubing setwas used to sort the cells using the manufacturer's CD133 Depletionprotocol (loading speed: 10 mL per min, 3 re-loads). The Treg enrichedcells were collected in the positive fraction and the remaining cellswere collected in the negative fraction.

The Treg enriched fraction was stained with anti-CD25 PE, CD4PerCP,CD127APC, CD45RA-FITC, and CD45RO-APC-Cy7 according to themanufacturer's instructions. Excess antibody was removed by washing thecells with buffer. The Treg enriched fraction was counted on a BeckmanCoulter Cytoflex using reference beads and used to calculate percentpurity and yield. The performance of the separation of Tregs from PBMCswas assessed by calculating the purity and yield of Treg cells in theenriched fraction relative to the pre-enriched cells.

FIG. 23A demonstrates that the Treg positive fraction comprised 88.5%CD4⁺ CD25⁺ cells, of which 81.0% were CD127⁺. In addition, FIG. 23Ademonstrates that the CD4⁺ CD25⁺ CD127⁺ cell population (Tregs) comprise67.1% memory Treg (CD45RO⁺) and 17.8% naïve Treg (CD45RA⁺). FIG. 23Bprovides a summary of the purity and yield of overall Tregs and NaïveTregs in the Treg positive fraction.

This data demonstrates that the methods described herein provide apopulation of Tregs that include a significant number of naïve Tregsthat would otherwise be lost during a CD45RA depletion step.

Example 9 Biotinylation of 6B11

6B11 is an antibody that binds to the invariant TCR Va24Ja18. However,the potency and specificity of this reagent when conjugated to secondaryfluorophores or other molecular handles is of poor performance ingeneral. However, when biotinylation conditions are varied using anunexpectedly good performance can be achieved.

A 6B11 hybridoma was modified at pH 7.5 in PBS for 2 hours with EZ-LINKSulfo-NHS-Biotin (ThermoFisher) at three different concentrations 1 hourand then desalted. The biotinylated antibodies and conditions are asfollows: 6B11.1=100 μM (condition 1); 6B11.2=250 μM (condition 2); and6B11.3=1 mM (condition 3).

iNKT cells were analyzed with 6B11.1 (condition 1), 6B11.2 (condition2), or 6B11.3 (condition 3) antibodies to assess binding to cell samplesfrom three different donors (Donor 73, Donor 74, and Donor 75) atincreasing concentrations of 6B11 antibody (0 μg/μL, 0.015 μg/μL, 0.032μg/μL, 0.062 μg/μL, 0.0125, 0.25 μg/μL, 0.5 μg/μL, and 1 μg/μL). FIG.24A shows that the 6B11.2 biotinlyated antibody had superiorperformance.

iNKT cells were analyzed with 6B11.1 (condition 1), 6B11.2 (condition2), or 6B11.3 (condition 3) antibodies, in conjunction with CD127 andstreptavidin PE-Cy7. FIG. 24B shows that condition 2 provided theclearest separation of iNKT cells (4.85%). The scatter plots depictedwere pre-gated on CD3+ single cell lymphocytes.

The various embodiments described above can be combined to providefurther embodiments. All of the U.S. patents, U.S. patent applicationpublications, U.S. patent applications, foreign patents, foreign patentapplications and non-patent publications referred to in thisspecification, including but not limited to U.S. Provisional PatentApplication No. 62/421,979, filed on Nov. 14, 2016, are incorporatedherein by reference, in their entirety except where incorporation of areference or a portion thereof contradicts with the present disclosure.Aspects of the embodiments can be modified, if necessary to employconcepts of the various patents, applications and publications toprovide yet further embodiments.

These and other changes can be made to the embodiments in light of theabove-detailed description. In general, in the following claims, theterms used should not be construed to limit the claims to the specificembodiments disclosed in the specification and the claims, but should beconstrued to include all possible embodiments along with the full scopeof equivalents to which such claims are entitled. Accordingly, theclaims are not limited by the disclosure.

What is claimed is:
 1. A pharmaceutical composition comprising one ormore unit doses of a cellular graft, wherein each unit dose of thecellular graft comprises populations of therapeutic cells for eachkilogram (kg) of body weight of a subject receiving the cellular graft,and wherein the populations of therapeutic cells of each unit dosecomprise: more than 3×10⁵ hematopoietic stem/progenitor cells (HSPC),more than 3×10⁵ memory T cells (Tmem), more than 5×10⁵ regulatory Tcells (Treg), and less than 3×10⁵ naïve conventional αβ-T cells.
 2. Thepharmaceutical composition of claim 1, wherein the unit dose furthercomprises 0.5×10³ to 2000×10³ invariant natural killer T (iNKT) cells.3. The pharmaceutical composition of claim 1, wherein the HSPC areCD34⁺, the Tmem are CD3⁺CD45RA⁻CD45RO⁺, the Treg areCD4⁺CD25⁺CD127^(−/lo) CD45RA⁺, or a combination thereof, and the naïveconventional αβ-T cells are CD3⁺CD45RA⁺CD25⁻TCR Va24Ja18⁻.
 4. Thepharmaceutical composition of claim 2, wherein the iNKT areCD3⁺Vα24Jα18⁺.
 5. The pharmaceutical composition of claim 1, where thepopulations of therapeutic cells of each unit dose comprise: 1.0×10⁶ to50×10⁶ HSPC, 0.3×10⁶ to 1000×10⁶ Tmem, 0.5×10⁶ to 1000×10⁶ Treg, andless than 3×10⁵ naïve conventional αβ-T cells.
 6. The pharmaceuticalcomposition of claim 1, wherein the unit dose further comprises iNKTcells, where the populations of therapeutic cells of each unit dosecomprise: 1.0×10⁶ to 50×10⁶ HSPC, 0.3×10⁶ to 1000×10⁶ Tmem, 0.5×10⁶ to1000×10⁶ Treg, 0.5×10³ to 2000×10³ iNKT, and less than 3×10⁵ naïveconventional αβ-T cells.
 7. The pharmaceutical composition of claim 1,where the populations of therapeutic cells of each unit dose comprises0.2×10⁶ to 500×10⁶ naïve Treg cells.
 8. The pharmaceutical compositionof claim 2, where the populations of therapeutic cells of each unit dosecomprises 0.2×10⁶ to 500×10⁶ naïve Treg cells.
 9. The pharmaceuticalcomposition of claim 1, where the populations of therapeutic cells ofeach unit dose comprises 1.0×10⁶ to 50×10⁶ HSPC.
 10. The pharmaceuticalcomposition of claim 1, where the populations of therapeutic cells ofeach unit dose comprises 1.0×10⁶ to 250×10⁶ Tmem.
 11. The pharmaceuticalcomposition of claim 1, where the populations of therapeutic cells ofeach unit dose comprises less than 1×10⁵ naïve conventional αβ-T cells.12. The pharmaceutical composition of claim 1, where the populations oftherapeutic cells of each unit dose comprises 1×10⁶ to 2.5×10⁶ Tregcells
 13. The pharmaceutical composition of claim 1, wherein the unitdose further comprises 1×10⁴ to 200×10⁴ iNKT.
 14. A pharmaceuticalcomposition comprising a population of therapeutic cells that isenriched for hematopoietic stem/progenitor cells (HSPC), memory T cells(Tmem), and regulatory T cells (Treg), and wherein the population ofcells is depleted of naïve conventional αβ-T cells, wherein thepopulation of therapeutic cells comprises a ratio of naïve conventionalαβ-T cells to Treg less than 1:5.
 15. The pharmaceutical composition ofclaim 14, wherein the population of therapeutic cells comprisesinvariant Natural Killer T cells (iNKT) and the population oftherapeutic cells comprises a ratio of naïve conventional αβ-T cells toiNKT less than 100:1.
 16. The pharmaceutical composition of claim 14,wherein the population of therapeutic cells comprises: a ratio of naïveconventional αβ-T cells to HSPC that is less than 1:400; and a ratio ofnaïve conventional αβ-T cells to Tmem less than 1:800.
 17. Thepharmaceutical composition of claim 14, wherein the population oftherapeutic cells comprises iNKT and population of therapeutic cellscomprises: a ratio of naïve conventional αβ-T cells to HSPC less than1:400; a ratio of naïve conventional αβ-T cells to Tmem less than 1:800;and a ratio of naïve conventional αβ-T cells to iNKT is less than 100:1.18. The pharmaceutical composition of claim 14, wherein the populationof therapeutic cells comprises a ratio of naïve conventional αβ-T cellsto HSPC less than 1:400.
 19. The pharmaceutical composition of claim 14,wherein the population of therapeutic cells comprises a ratio of naïveconventional αβ-T cells to Tmem less than 1:3.
 20. The pharmaceuticalcomposition of claim 14, wherein the population of therapeutic cellscomprises a ratio of naïve conventional αβ-T cells to naïve Treg lessthan 1:2.